Method for manufacturing photofunctional contact lenses
A method for manufacturing contact lenses with photochemical functionality limited to the pupil region addresses cosmetic issues and handling challenges by using controlled curing and composition concentrations, achieving a lens with focused photochemical effects.
Patent Information
- Application Number
- KR1020237028282
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-03-08
- Filing Date
- 2022-03-07
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2042-03-07
AI Technical Summary
Conventional methods for manufacturing photochromic contact lenses result in uniform discoloration across the lens, which is undesirable for cosmetic reasons, and handling high-viscosity photochromic compounds is challenging.
A method involving two polymerizable fluid compositions with controlled concentrations and curing times is used to create a contact lens with photochemical functionality limited to the central pupil region, utilizing a first composition without photochemical compounds and a second composition with photochemical compounds, and specific curing steps to form a concentric central region with photochemical functionality.
The method produces a contact lens with photochemical functionality confined to the pupil area, avoiding cosmetic issues and handling challenges, ensuring uniformity and minimizing adverse effects on appearance.
Smart Images

Figure 112023091563575-PCT00119_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a method for manufacturing a contact lens, in particular a silicone hydrogel contact lens having at least one optical function. The present invention also provides a contact lens manufactured according to the method of the present invention. Background Technology
[0002] Typically, UV-absorbing compounds are incorporated into contact lenses to manufacture UV-absorbing contact lenses that protect the eyes from ultraviolet rays. Recently, various photochromic contact lenses for protecting the eyes from ultraviolet rays have been proposed (see, for example, U.S. Patents No. 4681412, 6017121, 6174464, 6224945, 7261844, 7368072, 7556750, 7560056, 7584630, 7641337, 7999989, 8158037, 8697770, 8741188, 9052438, 9097916, 9377569, 9465234, 9904074, 10197707). These proposed photochromic contact lenses include a photochromic compound capable of undergoing a reversible color change, for example, from "clear" to blue or another color, upon exposure to UV / HEVL radiation.
[0003] Generally, photochromic contact lenses can be obtained by adding a photochromic compound to a polymerizable composition (i.e., lens formulation) for forming a contact lens, and then curing the polymerizable composition in a contact lens mold according to a cast-molded lens manufacturing process. A typical cast-molded lens manufacturing process includes the following steps: a single curing (polymerization) step of a single polymerizable composition (lens formulation) within a single-use plastic mold, generally composed of two single-molded halves; a mold opening step; optionally but preferably a lens delensing step (i.e., removing the cast-molded lens from the mold); and various post-molding process application steps, including extraction, hydration, packaging, sterilization, etc.
[0004] However, photochromic contact lenses obtained by such conventional cast-molding processes have a photochromic compound uniformly incorporated within the polymer matrix of the photochromic contact lens and may undergo reversible discoloration upon exposure to UV / HEVL radiation from edge to edge. Such photochromic contact lenses are undesirable for cosmetic reasons. It would be desirable to produce photochromic contact lenses that change color only in the central pupil area.
[0005] U.S. Patents No. 7368072, 7560056, 8697770, and 9904074 disclose a method for manufacturing a photochromic contact lens in which only the central pupil region may undergo reversible discoloration upon exposure to UV / HEVL radiation. This method comprises the following steps: introducing a photochromic lens-forming composition into the central region of the molding surface of a mold half, and then adding a clear lens-forming composition on top of the photochromic lens-forming composition (the photochromic lens-forming composition has a much higher viscosity than the clear lens-forming composition); aligning with the other mold half to form a cavity having the photochromic clear lens-forming composition inside; and curing the photochromic clear lens-forming composition within the cavity of the mold to form a photochromic contact lens. However, handling and introducing high-viscosity photochromic lens-forming compositions may be difficult in a production environment.
[0006] Therefore, there is still a need for a method to manufacture a hydrogel contact lens in which only the central pupil region has at least one photofunctionality.
[0007] The present invention provides a method for manufacturing a hydrogel contact lens, comprising, in some embodiments, the following steps: (1) obtaining a first polymerizable fluid composition and a second polymerizable fluid composition (the first polymerizable fluid composition comprises at least one photoinitiator and at least one polymerizable material and is free of any photochemical functional compounds, and the second polymerizable fluid composition comprises the at least one photoinitiator and the at least one polymerizable material and additionally at least one photochemical functional compound, wherein the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable fluid composition and the second polymerizable fluid composition is about 5.0% or less, and the at least one photochemical functional compound is at least one photochromic compound, at least one UV / HEVL absorbing compound, at least one fluorescent compound, at least one color-filtering material for colorblind correction, at least one diffracting material, at least one high refractive index material, or a combination thereof, the first polymerizable fluid composition has a first curing time and the second polymerizable fluid composition has a second curing time, and the first and (2) a step of obtaining a lens mold comprising a female mold half having a first molding surface defining the front surface of the contact lens to be molded and a male mold half having a second molding surface defining the rear surface of the contact lens to be molded, wherein the female and male mold half accommodate each other when the mold is closed to form a mold cavity between the first and second molding surfaces; (3) a step of applying a predetermined amount of a second polymerizable fluid composition onto the central area of the first molding portion of the female mold half to form a circular layer of the second polymerizable fluid composition (the diameter of the circular layer is about 13.(4) irradiating a circular layer of the second polymerizable fluid composition with UV / visible light of a specific intensity for about 5% to about 75% of the second curing time to partially crosslink the circular layer of the second polymerizable fluid composition; (5) distributing a predetermined amount of the first polymerizable fluid composition onto the partially crosslinked circular layer on the central area of the first molding surface; (6) closing the female mold half with the male mold half to form a molded assembly comprising the partially crosslinked circular layer immersed in the first polymerizable fluid composition within the mold cavity; (7) a step of irradiating a molded assembly with UV / visible light of a specific intensity for at least about 120% of the first curing time to form a raw hydrogel contact lens having a central region, wherein the central region is concentric with the central axis of the raw hydrogel contact lens, has a diameter of about 13 mm or less, and has at least one photochemical functionality provided by the at least one photochemical functional compound; (8) a step of separating the molded assembly into a male mold half and a female mold half with the raw hydrogel contact lens attached to a lens-attached mold half, which is one of the male and female mold halfs; (9) a step of removing the raw hydrogel contact lens from the lens-attached mold half; and (10) a step of applying the unprocessed hydrogel contact lens to a post-molding process comprising a hydration process and one or more other processes selected from the group consisting of extraction, surface treatment, packaging, sterilization and combinations thereof.
[0008] In another aspect, the present invention provides a contact lens manufactured according to the method of the present invention. Brief explanation of the drawing
[0009] FIG. 1 schematically illustrates a hydrogel contact lens according to a preferred embodiment of the present invention. Figure 2 shows the photorheological study of lens formulations 2A and 2B. Figure 3 shows the photorheological study of lens formulations 3A and 3B. FIG. 4 shows the UV / visible light absorption spectra of the central photochromic zone and the peripheral zone (outside the central photochromic zone) of a hydrogel contact lens in "on" and "off" states according to a preferred embodiment of the present invention. Specific details for implementing the invention
[0010] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention pertains. In general, the nomenclature and laboratory procedures used herein are widely known and commonly used in the art. Conventional methods, such as those provided in the art and various general references, are used for these procedures. Where a term is provided in the singular form, the inventors also consider the plural form of the term. The nomenclature used herein and the laboratory procedures described below are widely known and commonly used in the art.
[0011] As used herein, “about” means that the number referred to as “about” includes 1 to 10% of the cited number added to or subtracted from the cited number.
[0012] "Optional" or "arbitrarily" means that the event or situation described later may or may not occur, and implies that the description includes cases where the event or situation occurs and cases where the event or situation does not occur.
[0013] "Contact lens" refers to a structure that may be placed on or within the wearer's eye. A contact lens may correct, improve, or alter the user's vision, but is not necessarily so. A contact lens may be any suitable material known in the art or subsequently developed, and may be a soft lens, a hard lens, or a hybrid lens.
[0014] "Hydrogel contact lens" refers to a contact lens comprising a hydrogel bulk (core) material. The hydrogel bulk material may be a non-silicone hydrogel material or, preferably, a silicone hydrogel (SiHy) material.
[0015] "Hydrogel" or "hydrogel material" refers to a cross-linked polymer material having a three-dimensional polymer network (i.e., a polymer matrix) that is insoluble in water but can retain 10 weight percent or more of water within its polymer matrix when fully hydrated (or equilibrated).
[0016] "Silicone hydrogel" or "SiHy" refers to a silicon-containing hydrogel obtained by copolymerizing a polymerizable composition comprising at least one silicon-containing vinyl monomer and / or at least one silicon-containing vinyl crosslinking agent.
[0017] As is known to those skilled in the art, “siloxane” or “silicon” interchangeably refers to a molecule having a -Si-O-Si- moiety in which each Si atom is accompanied by at least two substituents (organic groups) or at least one -Si-O-Si- moiety.
[0018] As used in this application, the term "non-silicon hydrogel" refers to a hydrogel that is theoretically free of silicon.
[0019] As used herein, "hydrophilic" describes a material or part thereof that associates more readily with water than lipids.
[0020] "Vinyl monomer" refers to a compound having one single ethylene-based unsaturated group, being soluble in a solvent, and capable of being polymerized by chemical rays or heat.
[0021] With respect to a compound or substance in a solvent, the term "soluble" means that the compound or material is dissolved in the solvent and can provide a solution at a concentration of about 0.5 weight% or more at room temperature (i.e., a temperature of about 22°C to about 26°C).
[0022] With respect to a compound or substance in a solvent, the term "insoluble" means that the compound or substance is dissolved in the solvent and can provide a solution at a concentration of less than 0.01 weight% at room temperature (as defined above).
[0023] The term "ethylenically unsaturated group" is used herein in a broad sense and is intended to encompass any group containing at least one >C=C< group. Exemplary ethylenically unsaturated groups include, without limitation, (meth)acryloyl ( and / or ), allyl, vinyl, styrenyl, or other C=C containing groups are included.
[0024] As used herein, in relation to the curing, crosslinking, or polymerization of a polymerizable composition, prepolymer, or material, "by chemical radiation" means that curing (e.g., crosslinking and / or polymerization) is performed by chemical radiation, such as, for example, UV / visible light irradiation. Thermal curing or chemical radiation curing methods are well known to those skilled in the art.
[0025] "Acrylic monomer" refers to a vinyl monomer having a single (meth)acryloyl group. Examples of acrylic monomers include (meth)acryloxy [or (meth)acryloyloxy] monomers and (meth)acrylamido monomers.
[0026] "(Met)acryloxy monomer" or "(Met)acryloyloxy monomer" is or It refers to a vinyl monomer having a single group.
[0027] "(Met)acrylamido monomer" is or (Here, Ro It refers to a vinyl monomer having one single group (which is H or C1-C4 alkyl).
[0028] The term "(meth)acrylamide" refers to methacrylamide and / or acrylamide.
[0029] The term "(meth)acrylate" refers to methacrylates and / or acrylates.
[0030] "N-vinyl amide monomer" is a vinyl group directly attached to the nitrogen atom of the amide group ( It refers to amide compounds having ).
[0031] "En monomer" refers to a vinyl monomer having a single en group.
[0032] "Hydrophilic vinyl monomer," "hydrophilic acrylic monomer," "hydrophilic (meth)acryloxy monomer," or "hydrophilic (meth)acrylamido monomer" each refers to a vinyl monomer, an acrylic monomer, a (meth)acryloxy monomer, or a (meth)acrylamido monomer that, as used herein, generally produces a homopolymer that is water-soluble or capable of absorbing 10 weight percent or more of water.
[0033] "Hypothecolytic vinyl monomer," "hydrophobic acrylic monomer," "hydrophobic (meth)acryloxy monomer," or "hydrophobic (meth)acrylamido monomer" respectively refer to a vinyl monomer, an acrylic monomer, a (meth)acryloxy monomer, or a (meth)acrylamido monomer that, as used herein, generally produces a homopolymer that is insoluble in water and capable of absorbing less than 10 weight percent of water.
[0034] As used in this application, the term “vinyl crosslinker” refers to an organic compound having at least two ethylene-based unsaturated groups. “Vinyl crosslinker” refers to a vinyl crosslinker having a molecular weight of 700 daltons or less.
[0035] "Polysiloxane segment" or "polydiorganosiloxane segment" are interchangeable It refers to a polymer chain segment (i.e., a divalent radical), where SN is an integer greater than or equal to 3, and R S1 and R S2 Each is independently C1-C 10 Alkyl; Phenyl; C1-C4-alkyl-substituted phenyl; C1-C4-alkoxy-substituted phenyl; Phenyl-C1-C6-alkyl; C1-C 10 Fluoroalkyl; C1-C 10 Fluoroether; aryl; aryl C1-C 18 Alkyl; -alk-(OC2H4) γ1 -OR o (Here, alk is a C1-C6 alkylene diradal, and R o is H or C1-C4 alkyl and γ1 is an integer from 1 to 10); hydroxyl group (-OH), carboxyl group (-COOH), -NR N1 -'s amino linker, -CONR N1 -amide linker of, -CONR N1 R N1 amide of, -OCONH- urethane linker, and C1-C4 alkoxy group, or linear hydrophilic polymer chain (where, R N1 and R N1 ' are independently hydrogen or C1-C 15 C2-C having at least one functional group selected from the group consisting of alkyls 40 It is selected from a group consisting of organic radicals.
[0036] "Polydiorganosiloxane vinyl crosslinker" or "polysiloxane vinyl crosslinker" interchangeably refers to a compound comprising at least one polysiloxane segment and at least two ethylene-based unsaturated groups.
[0037] "Linear polydiorganosiloxane vinyl crosslinker" or "linear polysiloxane vinyl crosslinker" interchangeably refers to a compound comprising a main chain that is terminated by one ethylene-based unsaturated group at each of the two ends of the main chain and comprises at least one polysiloxane segment.
[0038] "Chain-extended polydiorganosiloxane vinyl crosslinker" or "chain-extended polysiloxane vinyl crosslinker" interchangeably refers to a compound comprising at least two ethylene-based unsaturated groups and at least two polysiloxane segments (each pair of these is connected by one divalent radical).
[0039] The term "photochromic vinyl monomer" refers to a vinyl monomer having one colorless (or pale) form and one colored form, which can undergo a reversible change from the colorless form (or pale form) (or so-called "inactive form") to the colored form (or so-called "activated form") upon exposure to UV / HEVL radiation.
[0040] In relation to photochromic contact lenses, the terms "colorless or pale state" or "inactive state" refer to the original state of the photochromic contact lens prior to irradiation with UV / HEVL light. In this state, the photochromic contact lens is generally colorless or exhibits a faint color as observed with the naked eye.
[0041] In relation to photochromic contact lenses, the terms "tinted state" or "active state" refer to the state of a photochromic contact lens when irradiated with UV / HEVL light. In this state, the photochromic contact lens generally exhibits a dark color, as observed with the naked eye.
[0042] As used herein, the term "fluid" indicates that the material can flow like a liquid.
[0043] As used herein, the term “transparent” in relation to a polymerizable composition means that the polymerizable composition is a transparent solution or liquid mixture having a light transmittance of 85% or more (preferably 90% or more) in the range of 400 to 700 nm.
[0044] A free radical initiator may be either a photoinitiator or a thermal initiator. "Photoinitiator" refers to a chemical substance that initiates a free radical crosslinking / polymerization reaction using UV and / or visible light. "Thermal initiator" refers to a chemical substance that initiates a radical crosslinking / polymerization reaction using thermal energy.
[0045] The term "acyl germanium photoinitiator" refers to an organic germanium compound that is a germanium-based Norrish Type I photoinitiator and comprises one or more acrylcarbonyl groups connected to germanium. Examples of such acyl germanium photoinitiators are disclosed in U.S. Patents No. 7605190 and No. 10324311.
[0046] As used in this application, the term "polymer" means a material formed by polymerizing or crosslinking one or more monomers, macromonomers, prepolymers, or combinations thereof.
[0047] "Macromonomer" or "prepolymer" refers to a compound or polymer containing an ethylene-based unsaturated group and having a number average molecular weight of more than 700 daltons.
[0048] As used in this application, the term “molecular weight” of a polymeric material (including monomeric or macromonomeric materials) refers to the number average molecular weight unless specifically stated otherwise or test conditions otherwise indicated. Those skilled in the art will know of methods, e.g., gel permeation chromatography (GPC) using one or more of a refractive index detector, a low-angle laser light scattering detector, a multi-angle laser light scattering detector, a differential viscometer detector, a UV detector, and an infrared (IR) detector; and matrix-assisted desorption / ionization time-of-flight mass spectrometry (MALDI-TOF MS). 1 I know how to measure the molecular weight of polymers using methods such as ¹H NMR (proton nuclear magnetic resonance) spectroscopy.
[0049] The term "monovalent radical" refers to an organic radical obtained by removing a hydrogen atom from an organic compound and forming a bond with one other group within the organic compound. Examples include, without limitation, alkyl (by removing a hydrogen atom from an alkane), alkoxy (or alkoxyl) (by removing one hydrogen atom from the hydroxyl group of an alkyl alcohol), thiyl (by removing one hydrogen atom from the thiol group of an alkylthiol), cycloalkyl (by removing a hydrogen atom from a cycloalkane), cycloheteroalkyl (by removing a hydrogen atom from a cycloheteroalkane), aryl (by removing a hydrogen atom from the aromatic ring of an aromatic hydrocarbon), heteroaryl (by removing a hydrogen atom from any ring atom), amino (by removing one hydrogen atom from an amine), etc.
[0050] The term "divalent radical" refers to an organic radical obtained by removing two hydrogen atoms from an organic compound and forming two bonds with two other groups within the organic compound. For example, the alkylene divalent radical (i.e., alkylenyl) is obtained by removing two hydrogen atoms from an alkane, and the cycloalkylene divalent radical (i.e., cycloalkylenyl) is obtained by removing two hydrogen atoms from a cyclic ring.
[0051] In this application, the term “substituted” with respect to alkyl or alkylenyl means that the alkyl or alkylenyl replaces one hydrogen atom of the alkyl or alkylenyl and comprises at least one substituent selected from the group consisting of hydroxyl (-OH), carboxyl (-COOH), -NH2, sulfhydryl (-SH), C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylthio(alkyl sulfide), C1-C4 acylamino, C1-C4 alkylamino, di-C1-C4 alkylamino, and combinations thereof.
[0052] The term "terminal ethylene unsaturated group" refers to one ethylene unsaturated group at one of the two ends of the main chain (or backbone) of an organic compound as known to those skilled in the art.
[0053] "Blending vinyl monomer" refers to a vinyl monomer capable of dissolving both the hydrophilic and hydrophobic components of a polymerizable composition to form a solution.
[0054] In relation to SiHy contact lenses, "post-curing surface treatment" refers to a surface treatment process performed after the SiHy contact lens is formed by curing the SiHy lens formulation (i.e., polymerizing by heat or chemical radiation).
[0055] The terms "silicone hydrogel lens formulation" or "SiHy lens formulation" refer, interchangeably, to a polymerizable composition comprising all polymerizable components necessary to produce a SiHy contact lens or a SiHy lens bulk material, as is well known to those skilled in the art.
[0056] "UV absorbing vinyl monomer" means a compound comprising a UV absorbing moiety and an ethylene-based unsaturated group capable of absorbing or filtering UV radiation in the range of 200 nm to 400 nm, as understood by those skilled in the art.
[0057] "HEVL absorbing vinyl monomer" means a compound comprising an ethylene-based unsaturated group and an HEVL absorbing moiety capable of absorbing or filtering HEVL (high-energy-violet-light) radiation in the range of 380 nm to 440 nm, as understood by those skilled in the art.
[0058] "UVA" refers to radiation occurring at a wavelength of 315 to 380 nanometers; "UVB" refers to radiation occurring at a wavelength of 280 to 315 nanometers; and "Violet" refers to radiation occurring at a wavelength of 380 to 440 nanometers.
[0059] "UVA transmittance" (or "UVA %T"), "UVB transmittance" or "UVB %T", and "Violet transmittance" or "Violet %T" are calculated by the following formula.
[0060] UVA %T = Average transmittance between 315 nm and 380 nm % x 100
[0061] UVB %T = Average transmittance between 280 nm and 315 nm % x 100
[0062] Violet %T = Average transmittance between 380 nm and 440 nm % x 100
[0063] Intrinsic "oxygen permeability" of the material, Dk iε is the rate at which oxygen passes through a material. As used herein, in relation to hydrogels (silicone or non-silicone) or contact lenses, the term "oxygen permeability (Dk)" refers to the corrected oxygen permeability (Dk), measured at about 34°C to 35°C according to the procedure described in ISO 18369-4 and corrected for surface resistance to oxygen flux induced by boundary layer effects. c It means ). Oxygen permeability is typically expressed in bars, and "bar" is [(cm 3 Oxygen)(cm) / (cm 2 )(sec)(mm Hg)] x 10 -9 It is defined as.
[0064] The "oxygen permeability" of a lens or material, Dk / t, is the rate at which oxygen passes through a specific lens or material with an average thickness t [in mm] over the area being measured. Oxygen permeability is typically expressed in units of barr / mm, and "barr / mm" is [(cm 3 Oxygen) / (cm² 2 )(sec)(mm Hg)] x 10 -9 It is defined as.
[0065] In relation to contact lenses or materials, the terms "modulus" or "elastic modulus" refer to the tensile modulus or Young's modulus, which is a measure of the stiffness of the contact lens or material under tension. Methods for measuring the elastic modulus of SiHy materials or contact lenses are widely known to those skilled in the art. For example, all commercial contact lenses have a measured elastic modulus.
[0066] "Unprocessed state" refers to a contact lens obtained by casting-molding a polymerizable composition in a mold and not undergoing post-molding processes of extraction and / or hydration (i.e., not coming into contact with water or any organic solvent or any liquid after molding).
[0067] "Hand shape mold half" or "base curve mold half" refers interchangeably to a mold half having a molding surface that is a substantially convex surface defining the rear surface of a contact lens.
[0068] "Female mold half" or "front curved mold half" refers interchangeably to a mold half having a molding surface that is a substantially concave surface defining the front surface of a contact lens.
[0069] As used in this application, the terms “anterior surface,” “front surface,” “front surface,” or “FC surface” in relation to contact lenses refer interchangeably to the surface of the contact lens facing away from the eye during wear. The anterior surface (front surface) is generally substantially convex.
[0070] As used in this application, the terms “rear surface,” “back surface,” “base surface,” or “BC surface” in relation to contact lenses refer interchangeably to the surface of a contact lens or insert facing the eye during wear. The rear surface (back surface) is generally substantially concave.
[0071] In relation to contact lenses, "coating" means that the contact lens has a thin layer of material on its surface that is different from the bulk material of the contact lens and is obtained by surface treating the contact lens.
[0072] As used herein, "surface modification" or "surface treatment" means that the article has been treated by a surface treatment process that (1) applies a coating to the surface of the article, (2) adsorbs chemical species onto the surface of the article, (3) changes the chemical properties of chemical groups on the surface of the article (e.g., electrostatic charge), or (4) modifies the surface characteristics of the article differently. Exemplary surface treatment processes include, but are not limited to, surface treatment by energy (e.g., plasma, electrostatic charge, radiation, or other energy source), chemical treatment, grafting of hydrophilic vinyl monomers or macromonomers on the surface of an article, mold transfer coating process disclosed in U.S. Patent No. 6719929, incorporation of a wetting agent into a lens formulation for manufacturing contact lenses proposed in U.S. Patents No. 6367929 and No. 6822016, reinforced mold transfer coating disclosed in U.S. Patent No. 7858000, and hydrophilic coating consisting of the covalent attachment or physical deposition of one or more layers of one or more hydrophilic polymers on the surface of a contact lens disclosed in U.S. Patents No. 8147897, No. 8409599, No. 8557334, No. 8529057, and No. 9505184.
[0073] In relation to a material or contact lens, "hydrophilic surface" means that the material or contact lens has surface hydrophilicity characterized by having an average water contact angle of about 90 degrees or less, preferably about 80 degrees or less, more preferably about 70 degrees or less, and more preferably about 60 degrees or less.
[0074] "Average contact angle" means the water contact angle obtained by averaging the measurements of at least three individual contact lenses (static water contact angle measured by Sessile Drop).
[0075] In relation to contact lenses, the term "central axis" refers to a line passing through the geometric center of the anterior and posterior surfaces of the contact lens.
[0076] Generally, the present invention relates to a method for manufacturing contact lenses, particularly SiHy contact lenses, wherein each contact lens comprises at least one central region having photochemical functionality that is concentric with the central axis of the contact lens and has a diameter of about 13 mm or less.
[0077] FIG. 1 schematically illustrates a contact lens of the present invention. Contact lens ( 100 ) is the front surface( 102 ), opposite rear surface, central axis( 101 ), and contact lenses ( 100 The central axis of ) 101 Diameter concentric with ) 120 central area having ) 110 Includes ). Central zone( 110 ) is the front part( 112 It includes at least one photochemical functional compound distributed in the peripheral portion (including the central portion of the front surface) and providing photochemical functionality to the central region.
[0078] The present invention is partially based on the discovery that such contact lenses can be manufactured according to the following process: a first step of introduction - a step of applying a small amount of a first polymerizable fluid composition comprising at least one photochemical functional compound to a central portion of a molding surface to form a circular layer of the first polymerizable fluid composition; a first curing step - a step of partially curing the circular layer of the polymerizable fluid composition in situ in a female mold half; a second step of introduction - a step of introducing a predetermined amount of a second polymerizable fluid composition onto the partially cured circular layer on the molding surface of a female mold half; and a second curing step - a step of curing the second polymerizable fluid composition and the partially cured circular layer immersed therein in a mold cavity formed between the molding surfaces of the female mold half and the male mold half. The second polymerizable fluid composition is substantially identical to the first polymerizable fluid composition except that the at least one photochemical functional compound present in the first polymerizable fluid composition is absent.
[0079] It has been found that partial curing of the first polymerizable fluid composition can be achieved by controlling the amount of chemical radiation exposed to the circular layer of the female mold half (e.g., by controlling the exposure time of the chemical radiation). After partial curing, the polymerizable component in the partially cured circular layer of the first polymerizable fluid composition will not be able to diffuse into the second polymerizable fluid composition and thus will not be able to blend. However, the second polymerizable fluid composition may still be able to diffuse at least partially into the partially cured circular layer in the molding assembly. Subsequently, a subsequent curing step will produce a contact lens comprising at least one central zone having photochemical functionality, concentric with the central axis of the raw contact lens and having a diameter of about 13 mm or less.
[0080] The method of the present invention can provide the following benefits. First, the entire contact lens is manufactured from the same material. This approach can avoid problems with the physical integrity of the lens that often occur when the lens is composed of two different materials. Additionally, problems of delamination or lens distortion can be avoided because there is no change or minimal change in lens expansion in different parts of the contact lens. Furthermore, photochemical functionality is limited to the optical area of the contact lens, that is, the pupil area of the eye when worn. Any color associated with photochemical functionality would have minimized adverse effects on the perception of the end user and those around them.
[0081] In some embodiments, the present invention provides a method for manufacturing a hydrogel contact lens, comprising the following steps: (1) obtaining a first polymerizable fluid composition and a second polymerizable fluid composition (the first polymerizable fluid composition comprises at least one photoinitiator and at least one polymerizable material and is free of any photochemical functional compounds, and the second polymerizable fluid composition comprises the at least one photoinitiator and the at least one polymerizable material and additionally at least one photochemical functional compound, and the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable fluid composition and the second polymerizable fluid composition is about 5.0% or less, and the at least one photochemical functional compound is at least one photochromic compound, at least one UV / HEVL absorbing compound, at least one fluorescent compound, at least one color-filtering material for colorblind correction, at least one diffracting material, at least one high refractive index material, or a combination thereof, and the first polymerizable fluid composition has a first curing time and the second polymerizable fluid composition has a second curing time, and the first and (2) a step of obtaining a lens mold comprising a female mold half having a first molding surface defining the front surface of the contact lens to be molded and a male mold half having a second molding surface defining the rear surface of the contact lens to be molded, wherein the female and male mold half accommodate each other when the mold is closed to form a mold cavity between the first and second molding surfaces; (3) a step of applying a predetermined amount of a second polymerizable fluid composition onto the central area of the first molding portion of the female mold half to form a circular layer of the second polymerizable fluid composition (the diameter of the circular layer is about 13.(0 mm or less); (4) a step of partially crosslinking the circular layer of the second polymerizable fluid composition by irradiating it with UV / visible light of a specific intensity for about 5% to about 75% of the second curing time (preferably about 5% to about 65%, more preferably about 5% to about 50%, more preferably about 5% to about 40%); (5) a step of dispensing a predetermined amount of the first polymerizable fluid composition onto the partially crosslinked circular layer on the central area of the first molding surface; (6) a step of closing the female mold half with the male mold half to form a molded assembly comprising the partially crosslinked circular layer immersed in the first polymerizable fluid composition within the mold cavity; (7) a step of irradiating a molded assembly with UV / visible light of a specific intensity for at least about 120% of the first curing time to form a raw hydrogel contact lens having a central region, wherein the central region is concentric with the central axis of the raw hydrogel contact lens, has a diameter of about 13 mm or less, and has at least one photochemical functionality provided by the at least one photochemical functional compound; (8) a step of separating the molded assembly into a male mold half and a female mold half with the raw hydrogel contact lens attached to a lens-attached mold half, which is one of the male and female mold halfs; (9) a step of removing the raw hydrogel contact lens from the lens-attached mold half; and (10) a step of applying the unprocessed hydrogel contact lens to a post-molding process comprising a hydration process and one or more other processes selected from the group consisting of extraction, surface treatment, packaging, sterilization and combinations thereof.
[0082] According to the present invention, the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable fluid composition and the second polymerizable fluid composition is about 5.0% or less (preferably about 4.0% or less, more preferably about 3.0% or less, and even more preferably about 2.5%). Such difference It is understood that it is calculated as follows:
[0083]
[0084] ( and is the concentration of a specific component i (e.g., a photoinitiator or a polymerizable substance) in the first polymerizable fluid composition and the second polymerizable fluid composition, respectively).
[0085] Any polymerizable material known for or suitable for forming contact lenses may be used in the present invention.
[0086] In one embodiment, the first and second polymerizable fluid compositions can independently form a non-silicon hydrogel, and the at least one polymerizable material is (1) a first monomer mixture comprising (a) one or more hydrophilic vinyl monomers and (b) one or more components selected from the group consisting of one or more non-silicon vinyl crosslinking agents, non-silicon hydrophobic vinyl monomers, UV-absorbing vinyl monomers, and combinations thereof; or (2) a reactive mixture comprising (a) one or more water-soluble non-silicon prepolymers and optionally (b) one or more components selected from the group consisting of hydrophilic vinyl monomers, non-silicon vinyl crosslinking agents, non-silicon hydrophobic vinyl monomers, UV-absorbing vinyl monomers, and combinations thereof.
[0087] In another embodiment, the first and second polymerizable fluid compositions are for forming a silicon hydrogel independently of each other, wherein the at least one polymerizable material is a second monomer mixture comprising at least one component selected from the group consisting of (a) at least one silicon-containing vinyl monomer, (b) at least one polysiloxane vinyl crosslinker, at least one non-silicon vinyl crosslinker, or both, (c) at least one hydrophilic vinyl monomer, (d) at least one photoinitiator, and optionally (e) a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof.
[0088] Any hydrophilic vinyl monomer may be used in the present invention. Examples of preferred hydrophilic vinyl monomers include hydrophilic (meth)acrylamido (as described below in this application), hydrophilic (meth)acryloxy monomer (as described below in this application), hydrophilic N-vinylamide monomer (as described below in this application), methylene-containing pyrrolidone monomer (i.e., pyrrolidone derivatives having a methylene group connected to a pyrrolidone ring at the 3- or 5-position, respectively) (as described below in this application), vinyl ether monomer (as described below in this application), allyl ether monomer (as described below in this application), phosphorylcholine-containing vinyl monomer (as described below in this application), allyl alcohol, N-2-hydroxyethyl vinyl carbamate, N-vinyloxycarbonyl-β-alanine (VINAL), N-vinyloxycarbonyl-α-alanine, and combinations of these exist.
[0089] Any water-soluble non-silicon prepolymer may be used in the present invention. Examples of water-soluble non-silicon prepolymers include, without limitation: water-soluble chemical line crosslinkable poly(vinyl alcohol) prepolymers described in US5583163 and US6303687; water-soluble vinyl group-terminated polyurethane prepolymers described in US6995192; derivatives of polyvinyl alcohol, polyethyleneimine, or polyvinylamine disclosed in US5849841; water-soluble crosslinkable polyurea prepolymers described in US6479587 and US7977430; crosslinkable polyacrylamides; crosslinkable statistical copolymers of vinyl lactam, MMA, and comonomers disclosed in US5712356; and crosslinkable copolymers of vinyl lactam, vinyl acetate, and vinyl alcohol disclosed in US5665840. Polyether-polyester copolymer having crosslinkable side chains disclosed in US6492478; branched polyalkylene glycol-urethane prepolymer disclosed in US6165408; polyalkylene glycol-tetra(meth)acrylate prepolymer disclosed in US6221303; crosslinkable polyallylamine gluconolactone prepolymer disclosed in US6472489.
[0090] Any non-silicon vinyl crosslinker may be used in the present invention. Examples of preferred non-silicon vinyl crosslinkers are described below in this application.
[0091] Any non-silicon hydrophobic vinyl monomer may be used in the present invention. Examples of preferred hydrophobic non-silicon vinyl monomers include non-silicon hydrophobic acrylic monomers (e.g., alkyl (meth)acrylates as described below, cycloalkyl (meth)acrylates as described below, phenyl methacrylate, (meth)acrylonitrile, etc.), and fluorine-containing acrylic monomers (e.g., perfluorohexylethyl-thio-carbonyl-aminoethyl-methacrylate, perfluoro-substituted-C2-C as described below). 12Alkyl (meth)acrylates, etc.), vinyl alkanoates (e.g., vinyl acetate, vinyl propionate, vinyl butyrate, vinyl valerate, etc.), vinyloxyalkanes (e.g., vinyl ethyl ether, propyl vinyl ether, n-butyl vinyl ether, isobutyl vinyl ether, cyclohexyl vinyl ether, t-butyl vinyl ether, etc.), substituted or unsubstituted styrenes as described below, vinyl toluene, vinyl chloride, vinylidene chloride, 1-butene, and combinations thereof.
[0092] Any suitable perfluoro-substituted-C2-C 12 Alkyl (meth)acrylates may be used in the present invention. Perfluoro-substituted-C2-C 12 Examples of alkyl (meth)acrylates include, without limitation, 2,2,2-trifluoroethyl (meth)acrylate, tetrafluoropropyl (meth)acrylate, hexafluoro-iso-propyl (meth)acrylate, hexafluorobutyl (meth)acrylate, heptafluorobutyl (meth)acrylate, octafluoropentyl (meth)acrylate, heptadecafluorodecyl (meth)acrylate, pentafluorophenyl (meth)acrylate, and combinations thereof.
[0093] In a preferred embodiment, one or more hydrophobic non-silicon acrylic monomers and / or substituted or unsubstituted styrenes may be used in the present invention as reactive diluents (i.e., blending vinyl monomers) to dissolve other polymerizable components in the polymerizable composition of the present invention.
[0094] Examples of such non-silicon hydrophobic acrylic monomers and substituted or unsubstituted styrenes include methyl methacrylate, ethyl methacrylate, isopropyl methacrylate, sec-butyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, phenyl methacrylate, 4-tert-butylstyrene, 2-methylstyrene, styrene, 4-ethoxystyrene, 2,4-dimethylstyrene, 2,5-dimethylstyrene, 3,5-dimethylstyrene, and combinations thereof. More preferably, methyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, or combinations thereof are used in the present invention. More preferably, methyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, or a combination thereof is used in the present invention.
[0095] The term "UV / HEVL absorbing compound" refers to a compound capable of absorbing UV light and high-energy violet light (i.e., light having a wavelength of 380 nm to 440 nm). Preferred examples of UV / HEVL absorbing compounds include polymerizable UV / HEVL absorbing compounds, for example, Cu-porphrine derivatives each having one or more ethylene-based unsaturated groups, and UV / HEVL absorbing vinyl monomers.
[0096] The term "UV / HEVL absorbing vinyl monomer" means a vinyl monomer capable of absorbing UV light and high-energy violet light (i.e., light having a wavelength of 380 nm to 440 nm). Examples of UV absorbing vinyl monomers and UV / HEVL absorbing vinyl monomers are known to those skilled in the art and are disclosed in patents and patent application publications, e.g., US 9315669, US 2018-0081197 A1, etc.
[0097] Any suitable UV-absorbing vinyl monomer and UV / HEVL-absorbing vinyl monomer may be used in the present invention. Examples of preferred UV-absorbing and UV / HEVL-absorbing vinyl monomers include, without limitation, 2-(2-hydroxy-5-vinylphenyl)-2H-benzotriazole, 2-(2-hydroxy-5-acrylyloxyphenyl)-2H-benzotriazole, 2-(2-hydroxy-3-methacrylamidomethyl-5-tert-octylphenyl)benzotriazole, 2-(2'-hydroxy-5'-methacrylamidophenyl)-5-chlorobenzotriazole, 2-(2'-hydroxy-5'-methacrylamidophenyl)-5-methoxybenzotriazole, 2-(2'-hydroxy-5'-methacryloxypropyl-3'-t-butyl-phenyl)-5-chlorobenzotriazole, and 2-(2'-hydroxy-5'-methacryloxypropylphenyl). Benzotriazole, 2-hydroxy-5-methoxy-3-(5-(trifluoromethyl)-2H-benzo[d][1,2,3]triazole-2-yl)benzyl methacrylate (WL-1), 2-hydroxy-5-methoxy-3-(5-methoxy-2H-benzo[d][1,2,3]triazole-2-yl)benzyl methacrylate (WL-5), 3-(5-fluoro-2H-benzo[d][1,2,3]triazole-2-yl)-2-hydroxy-5-methoxybenzyl methacrylate (WL-2), 3-(2H-benzo[d][1,2,3]triazole-2-yl)-2-hydroxy-5-methoxybenzyl methacrylate (WL-3), 3-(5-chloro-2H-benzo[d][1,2,3]triazole-2-yl)-2-hydroxy-5-methoxybenzyl methacrylate (WL-4), 2-hydroxy-5-methoxy-3-(5-methyl-2H-benzo[d][1,2,3]triazole-2-yl)benzyl methacrylate (WL-6), 2-hydroxy-5-methyl-3-(5-(trifluoromethyl)-2H-benzo[d][1,2,3]triazole-2-yl)benzyl methacrylate (WL-7), 4-allyl-2-(5-chloro-2H-benzo[d][1,2,3]triazole-2-yl)-6-methoxyphenol (WL-8), 2-{2'-hydroxy-3'- tert -5'[3"-(4"-vinylbenzyloxy)propoxy]phenyl}-5-methoxy- 2H -Benzotriazole, phenol, 2-(5-chloro-2H -benzotriazole-2-yl)-6-(1,1-dimethylethyl)-4-ethenyl- (UVAM), 2-[2'-hydroxy-5'-(2-methacryloxyethyl)phenyl)]-2H-benzotriazole (2-propenic acid, 2-methyl-, 2-[3-(2 H -benzotriazole-2-yl)-4-hydroxyphenyl]ethyl ester, Norbloc), 2-{2'-hydroxy-3'- tert -butyl-5'-[3'-methacryloyloxypropoxy]phenyl}- 2H -Benzotriazole, 2-{2'-hydroxy-3'- tert -butyl-5'-[3'-methacryloyloxypropoxy]phenyl}-5-methoxy- 2H -Benzotriazole (UV13), 2-{2'-hydroxy-3'- tert -butyl-5'-[3'-methacryloyloxypropoxy]phenyl}-5-chloro- 2H -Benzotriazole (UV28), 2-[2'-hydroxy-3'- tert -butyl-5'-(3'-acryloyloxypropoxy)phenyl]-5-trifluoromethyl- 2H -Benzotriazole (UV23), 2-(2'-hydroxy-5-methacrylamidophenyl)-5-methoxybenzotriazole (UV6), 2-(3-allyl-2-hydroxy-5-methylphenyl)- 2H -Benzotriazole (UV9), 2-(2-hydroxy-3-metallyl-5-methylphenyl)- 2H -Benzotriazole (UV12), 2-3'-t-butyl-2'-hydroxy-5'-(3"-dimethylvinylsilylpropoxy)-2'-hydroxy-phenyl)-5-methoxybenzotriazole (UV15), 2-(2'-hydroxy-5'-methacryloylpropyl-3'-tert-butyl-phenyl)-5-methoxy- 2H -Benzotriazole (UV16), 2-(2'-hydroxy-5'-acryloylpropyl-3'-tert-butyl-phenyl)-5-methoxy- 2H-Benzotriazole (UV16A), 2-methylacrylic acid 3-[3-tert-butyl-5-(5-chlorobenzotriazole-2-yl)-4-hydroxyphenyl]-propyl ester (16-100, CAS#96478-15-8), 2-(3-(tert-butyl)-4-hydroxy-5-(5-methoxy-2H-benzo[d][1,2,3]triazole-2-yl)phenoxy)ethyl methacrylate (16-102); phenol, 2-(5-chloro-2 H -benzotriazole-2-yl)-6-methoxy-4-(2-propene-1-yl) (CAS#1260141-20-5); 2-[2-hydroxy-5-[3-(methacryloyloxy)propyl]-3- tert -butylphenyl]-5-chloro-2 H -Benzotriazole; phenol, 2-(5-ethenyl-2H-benzotriazole-2-yl)-4-methyl-, homopolymer (9CI) (CAS#83063-87-0) is included. According to the present invention, the polymerizable composition comprises one or more UV-absorbing vinyl monomers in an amount of about 0.1% to about 3.0% by weight, preferably about 0.2% to about 2.5% by weight, more preferably about 0.3% to about 2.0% by weight, with respect to the amount of all polymerizable components in the polymerizable composition.
[0098] Any silicon-containing vinyl monomer may be used in the present invention. Examples of preferred silicon-containing vinyl monomers may be silicon-containing (meth)acrylamido monomers, silicon-containing (meth)acryloxy monomers, silicon-containing vinylcarbonato monomers, or silicon-containing vinylcarbamato monomers, each of which comprises a bis(trialkylsilyloxy)alkylsilyl group, a tris(trialkylsilyloxy)-silyl group, or a polysiloxane chain having 2 to 30 siloxane units and terminated with an alkyl, hydroxyalkyl, or methoxyalkyl group. Such desirable silicon-containing vinyl monomers may be available from commercial suppliers or, alternatively, vinyl having a reactive functional group (e.g., acid chloride, acid anhydride, carboxyl, amino, epoxy, isocyanate, aziridine, azlactone, or aldehyde group) in accordance with known procedures, e.g., U.S. Patents No. 5070215, 6166236, 6867245, 7214809, 8415405, 8475529, 8614261, 8658748, 9097840, 9103965, 9217813, 9315669, and 9475827) or in the presence or absence of a coupling agent under coupling reaction conditions well known to those skilled in the art, or in accordance with known procedures (e.g., similar to those described in U.S. Patents No. 5070215, 6166236, 6867245, 7214809, 8415405, 8475529, 8614261, 8658748, 9097840, 9103965, 9217813, 9315669, and 9475827), or under coupling reaction conditions well known to those skilled in the art. It can be prepared by reacting a monomer with a siloxane-containing compound selected from the group consisting of hydroxyalkyl, aminoalkyl, alkylaminoalkyl, carboxyalkyl, isocyanatoalkyl, epoxyalkyl, and aziridinylalkyl.
[0099] In a preferred embodiment, the at least one silicon-containing vinyl monomer comprises a bis(trialkylsilyloxy)alkylsilyl group, a tris(trialkylsilyloxy)silyl group, or at least one silicon-containing (meth)acrylamido monomer having a polysiloxane chain having 2 to 30 siloxane units and terminated with an alkyl, hydroxyalkyl, or methoxyalkyl group. Examples of such preferred silicon-containing (meth)acrylamido monomers include, but are not limited to, those described below in this application.
[0100] In another preferred embodiment, the at least one silicon-containing vinyl monomer comprises a bis(trialkylsilyloxy)alkylsilyl group, a tris(trialkylsilyloxy)silyl group, or at least one silicon-containing (meth)acryloxy monomer having a polysiloxane chain having 2 to 30 siloxane units and terminated with an alkyl, hydroxyalkyl, or methoxyalkyl group. Examples of such preferred silicon-containing (meth)acryloxy monomers include, but are not limited to, those described below in this application.
[0101] Any polysiloxane vinyl crosslinker may be used in the present invention. Preferred examples of polysiloxane vinyl crosslinkers include α,ω-(meth)acryloxy-terminated polydimethylsiloxane; α,ω-(meth)acrylamido-terminated polydimethylsiloxane; α,ω-vinyl carbonate-terminated polydimethylsiloxane; α,ω-vinyl carbamate-terminated polydimethylsiloxane; bis-3-methacryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane; reaction product of glycidyl methacrylate and amino-functional polydimethylsiloxane; reaction product of an azlactone-containing vinyl monomer (any one of those described above) and hydroxyl-functional polydimethylsiloxane; A polysiloxane-containing macromonomer selected from the group consisting of macromonomer A, macromonomer B, macromonomer C, and macromonomer D as described in US 5,760,100; U.S. Patents No. 4136250, No. 4153641, No. 4182822, No. 4189546, No. 4259467, No. 4260725, No. 4261875, No. 4343927, No. 4254248, No. 4355147, No. 4276402, No. 4327203, No. 4341889, No. 4486577, No. 4543398, No. 4605712, No. 4661575, No. 4684538, No. 4703097, No. 4833218, No. 4837289, No. 4954586, No. 4954587, No. 5010141, No. 5034461, No. 5070170, No. 5079319, No. 5039761, No. 5346946, No. 5358995, No. 5387632, No. 5416132, No. 5449729, No. 5451617, No. 5486579, No. 5962548, No. 5981675, No. 6039913, No. 6762264, No. 7423074, No. 8163206, No. 8480227, No. 8529057, No. 8835525, No. 8993651, No. 9,187,601, No. 10081697, No. 10301451, and It includes, but is not limited to, the polysiloxane vinyl crosslinking agent disclosed in Patent No. 10465047.
[0102] One class of preferred polysiloxane vinyl crosslinkers is a monovalent C4-C having 2 to 6 hydroxyl groups. 40 A di-(meth)acryloyloxy-terminated polysiloxane vinyl crosslinker having a hydrophilized siloxane unit having an organic radical substituent and a dimethylsiloxane unit having a methyl substituent, respectively, and more preferably a polysiloxane vinyl crosslinker of formula H, which can be prepared according to the procedure disclosed in U.S. Patent No. 10081697 and described below in this application.
[0103] Another class of preferred polysiloxane vinyl crosslinkers is vinyl crosslinkers (each having one homogeneous polydiorganosiloxane segment and two terminal (meth)acryloyl groups), which may be available from commercial sources; may be prepared by reacting glycidyl (meth)acrylate (meth)acryloyl chloride with di-amino-terminated polydimethylsiloxane or di-hydroxyl-terminated polydimethylsiloxane; may be prepared by reacting isocyanatoethyl (meth)acrylate with di-hydroxyl-terminated polydimethylsiloxane; or may be prepared by reacting an amino-containing acrylic monomer with di-carboxyl-terminated polydimethylsiloxane in the presence of a coupling agent (carbodiimide); It can be prepared by reacting a carboxyl-containing acrylic monomer with a di-amino-terminated polydimethylsiloxane in the presence of a coupling agent (carbodiimide); or it can be prepared by reacting a hydroxyl-containing acrylic monomer with a di-hydroxy-terminated polydisiloxane in the presence of a diisocyanate or a di-epoxy coupling agent.
[0104] Another class of preferred polysiloxane vinyl crosslinkers is a chain-extended polysiloxane vinyl crosslinker having at least two polydiorganosiloxane segments connected by a linker between each pair of two terminal ethylene-based unsaturated groups and a polydiorganosiloxane segment, which can be manufactured according to the procedures described in U.S. Patents No. 5034461, No. 5416132, No. 5449729, No. 5760100, No. 7423074, No. 8529057, No. 8835525, No. 8993651, No. 9187601, No. 10301451, and No. 10465047.
[0105] Any hydrophilic vinyl monomer may be used in the present invention. Examples of preferred hydrophilic vinyl monomers include hydrophilic (meth)acrylamido (as described below in this application), hydrophilic (meth)acryloxy monomer (as described below in this application), hydrophilic N-vinylamide monomer (as described below in this application), methylene-containing pyrrolidone monomer (i.e., pyrrolidone derivatives having a methylene group connected to a pyrrolidone ring at the 3- or 5-position, respectively) (as described below in this application), vinyl ether monomer (as described below in this application), allyl ether monomer (as described below in this application), phosphorylcholine-containing vinyl monomer (as described below in this application), allyl alcohol, N-2-hydroxyethyl vinyl carbamate, N-vinyloxycarbonyl-β-alanine (VINAL), N-vinyloxycarbonyl-α-alanine, and combinations of these exist.
[0106] In another preferred embodiment, the one or more hydrophilic vinyl monomers preferably comprise one or more hydrophilic (meth)acrylamido monomers having 3 to 10 carbon atoms. Examples of preferred hydrophilic (meth)acrylamido monomers are described below in this application. It is determined that such hydrophilic (meth)acrylamido monomers can be used to increase the glass transition temperature of the resulting silicon hydrogel material. Furthermore, it is understood that any hydrophilic (meth)acrylamido monomer other than those specifically described below in this application may also be used in the present invention.
[0107] In another preferred embodiment, the at least one hydrophilic vinyl monomer comprises at least one hydrophilic N-vinylamide monomer. Examples of preferred hydrophilic N-vinylamide monomers are described below in this application. It is understood that any hydrophilic N-vinylamide monomer other than those specifically described below in this application may also be used in the present invention.
[0108] In another preferred embodiment, the one or more hydrophilic vinyl monomers preferably comprise one or more hydrophilic (meth)acryloxy monomers having 3 to 10 carbon atoms. Examples of preferred hydrophilic (meth)acryloxy monomers are described below in this application. It is understood that any hydrophilic (meth)acryloxy monomer other than those specifically described below in this application may also be used in the present invention.
[0109] In a preferred embodiment, the sum of the amounts of components (a), (b), and (c) in the second monomer mixture is about 60% or more (preferably about 65% or more, more preferably about 70% or more, even more preferably about 75% or more) with respect to the total weight of all polymerizable materials in the first polymerizable fluid composition.
[0110] Suitable photoinitiators are benzoin methyl ether, diethoxyacetophenone, benzoylphosphine oxide, 1-hydroxycyclohexyl phenyl ketone and Darocur and Irgacur types, preferably Darocur 1173® and Darocur 2959®, germanium photoinitiators.
[0111] Examples of benzoylphosphine initiators include 2,4,6-trimethylbenzoyldiphenyl-phosphine oxide; bis-(2,6-dichlorobenzoyl)-4-N-propylphenylphosphine oxide; and bis-(2,6-dichlorobenzoyl)-4-N-butylphenylphosphine oxide.
[0112] Any acyl-germanium photoinitiator may be used in the present invention as long as it can initiate free radical polymerization by irradiating a light source containing light in the range of about 420 to about 500 nm. An example of an acyl-germanium photoinitiator is an acyl-germanium compound described in U.S. Patent No. 7605190. Preferably, the at least one first and / or second free radical initiator comprises at least one of the following acyl-germanium compounds.
[0113] , , and
[0114] The first (second) polymerizable fluid composition of the present invention may also include other essential components known to those skilled in the art, examples thereof as known to those skilled in the art, such as a visibility coloring agent (e.g., one or more polymerizable dyes, pigments, or mixtures thereof), an antimicrobial agent (e.g., silver nanoparticles), a bioactive agent (e.g., drugs, amino acids, polypeptides, proteins, nucleic acids, 2-pyrrolidone-5-carboxylic acid (PCA), alpha hydroxylic acids, linoleic acid, and gamma linoleic acid, vitamins, or combinations thereof), an leaching lubricant (e.g., a non-crosslinked hydrophilic polymer having an average molecular weight of 5,000 to 500,000, preferably 10,000 to 300,000, more preferably 20,000 to 100,000 daltons), and an leaching tear stabilizer (e.g., phospholipids, monoglycerides, diglycerides, triglycerides, glycolipids, There are glyceroglycolipids, sphingolipids, sphingoglycolipids, fatty acids having 8 to 36 carbon atoms, fatty alcohols having 8 to 36 carbon atoms, or mixtures thereof), release agents and mixtures thereof.
[0115] According to the present invention, the first (second) polymerizable fluid composition of the present invention may be a solution or a solvent-free blend (i.e., a fluid composition without any non-reactive diluent-organic solvent). It may also be prepared according to any technique known to those skilled in the art.
[0116] The first (second) polymerizable fluid composition of the present invention may also be any known hydrogel lens formulation.
[0117] Numerous non-silicone hydrogel lens formulations have been described in numerous patents and patent applications disclosed up to the filing date of this application and have been used to manufacture commercially available non-silicone hydrogel contact lenses. Examples of commercially available non-silicone hydrogel contact lenses include, without limitation, alfafilcon A, acofilcon A, deltafilcon A, etafilcon A, focofilcon A, helfilcon A, helfilcon B, hilafilcon B, hioxifilcon A, hioxifilcon B, hioxifilcon D, methafilcon A, methafilcon B, nelfilcon A, nesofilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, omafilcon A, phemfilcon A, polymacon, samfilcon A, telfilcon A, tetrafilcon A, vifilcon A, etc.
[0118] Numerous SiHy lens formulations have been described in numerous patents and patent applications disclosed up to the filing date of this application and have been used to manufacture commercially available SiHy contact lenses. Examples of commercially available SiHy contact lenses include, without limitation, asmofilcon A, balafilcon A, comfilcon A, delefilcon A, efrofilcon A, enfilcon A, fanfilcon A, galyfilcon A, lotrafilcon A, lotrafilcon B, narafilcon A, narafilcon B, senofilcon A, senofilcon B, senofilcon C, smafilcon A, somofilcon A, and stenfilcon A.
[0119] Here, the first (second) polymerizable fluid composition of the present invention is a solution. It can be prepared by dissolving all desirable components in any suitable solvent known to those skilled in the art. Examples of suitable solvents include, without limitation, water, tetrahydrofuran, tripropylene glycol methyl ether, dipropylene glycol methyl ether, ethylene glycol n-butyl ether, ketones (e.g., acetone, methyl ethyl ketone, etc.), diethylene glycol n-butyl ether, diethylene glycol methyl ether, ethylene glycol phenyl ether, propylene glycol methyl ether, propylene glycol methyl ether acetate, dipropylene glycol methyl ether acetate, propylene glycol n-propyl ether, dipropylene glycol n-propyl ether, tripropylene glycol n-butyl ether, propylene glycol n-butyl ether, dipropylene glycol n-butyl ether, tripropylene glycol n-butyl ether, propylene glycol phenyl ether, dipropylene glycol dimethyl ether, polyethylene glycol, polypropylene glycol, and ethyl Acetate, butyl acetate, amyl acetate, methyl lactate, ethyl lactate, i-propyl lactate, methylene chloride, 2-butanol, 1-propanol, 2-propanol, methanol, cyclohexanol, cyclopentanol and exonorborneol, 2-pentanol, 3-pentanol, 2-hexanol, 3-hexanol, 3-methyl-2-butanol, 2-heptanol, 2-octanol, 2-nonanol, 2-decanol, 3-octanol, norborneol, tert-butanol, tert-amyl alcohol, 2-methyl-2-pentanol, 2,3-dimethyl-2-butanol, 3-methyl-3-pentanol, 1-methylcyclohexanol, 2-methyl-2-hexanol, 3,7-dimethyl-3-octanol, 1-chloro-2-methyl-2-propanol, 2-methyl-2-heptanol, 2-methyl-2-octanol, 2-2-methyl-2-nonanol, 2-methyl-2-decanol, 3-methyl-3-hexanol, 3-methyl-3-heptanol, 4-methyl-4-heptanol, 3-methyl-3-octanol, 4-methyl-4-octanol, 3-methyl-3-nonanol, 4-methyl-4-nonanol, 3-methyl-3-octanol, 3-ethyl-3-hexanol, 3-methyl-3-heptanol,4-ethyl-4-heptanol, 4-propyl-4-heptanol, 4-isopropyl-4-heptanol, 2,4-dimethyl-2-pentanol, 1-methylcyclopentanol, 1-ethylcyclopentanol, 1-ethylcyclopentanol, 3-hydroxy-3-methyl-1-butene, 4-hydroxy-4-methyl-1-cyclopentanol, 2-phenyl-2-propanol, 2-methoxy-2-methyl-2-propanol, 2,3,4-trimethyl-3-pentanol, 3,7-dimethyl-3-octanol, 2-phenyl-2-butanol, 2-methyl-1-phenyl-2-propanol, and 3-ethyl-3-pentanol, 1-ethoxy-2-propanol, 1-methyl-2-propanol, t-amyl alcohol, isopropanol, 1-methyl-2-pyrrolidone, N,N-dimethylpropionamide, dimethylformamide, dimethylacetamide, dimethylpropionamide, N-methylpyrrolidinone, and mixtures thereof are included. Preferably, the polymerizable composition is a solution of all preferred components among water, 1,2-propylene glycol, polyethylene glycol having a molecular weight of about 400 daltons or less, or a mixture thereof.
[0120] If the first (second) polymerizable fluid composition of the present invention is a solvent-free blend, it can be prepared by mixing all polymerizable components and other necessary components. The solvent-free polymerizable composition generally comprises at least one blending vinyl monomer as a reactive solvent for dissolving all other polymerizable components of the solvent-free polymerizable composition. Examples of preferred blending vinyl monomers are described above and below in this application. Preferably, methyl methacrylate is used as the blending vinyl monomer in the preparation of the solvent-free polymerizable composition.
[0121] According to the present invention, a second polymerizable fluid composition can be prepared by blending all components necessary to reach a desired concentration or, alternatively, by adding at least one photochemical functional compound to a first polymerizable fluid composition.
[0122] In a preferred embodiment, the at least one photochemical functional compound is one or more photochromic vinyl monomers. Any photochromic vinyl monomer may be used in the present invention. Examples of preferred photochromic vinyl monomers include polymerizable naphtopyran, polymerizable benzopyran, polymerizable indenonaphtopyran, polymerizable phenantropyran, as disclosed in U.S. Patents No. 4929693, 5166345, 6017121, 7556750, 7584630, 7999989, 8158037, 8697770, 8741188, 9052438, 9097916, 9465234, 9904074, 10197707, 6019914, 6113814, 6149841, 6296785, and 6348604. Polymerizable spiro(benzindoline)-naphtopyran, polymerizable spiro(indoline)benzopyran, polymerizable spiro(indoline)-naphtopyran, polymerizable spiro(indoline)quinopyran, polymerizable spiro(indoline)-pyran, polymerizable naphthoxazine, polymerizable spirobenzopyran; polymerizable spirobenzopyran, polymerizable spirobenzothiopyran, polymerizable naphthacendione, polymerizable spirooxazine, polymerizable spiro(indoline)naphthoxazine, polymerizable spiro(indoline)pyridobenzoxazine, polymerizable spiro(benzindoline)pyridobenzoxazine, polymerizable spiro(benzindoline)naphthoxazine, polymerizable spiro(indoline)benzoxazine, polymerizable spiro(indoline)benzoxazine, polymerizable dialylethene, and combinations thereof are included.
[0123] Various photochromic compounds are disclosed in patents and published patent applications and can be obtained from commercial sources or manufactured according to procedures described in patents and literature. Examples of preferred photochromic compounds include, without limitation, naphtopyran, indeno-fused naphtopyran (i.e., indeno-naphtopyran), heterocyclic ring-fused naphtopyran, benzopyran, phenantropyran, quinopyran, quinolinopyran, fluoroantenopyran, anthracene-fused pyran, tetracene-fused pyran, spiro(benzindolin)naphtopyran, spiro(indolin)naphtopyran, spiro(indolin)benzopyran, spiro(indolin)quinopyran, spiro(indolin)pyran, naphthoxazine, spirobenzopyran, spirobenzothiopyran, naphthacenedione, benzoxazine, spirooxazine, naphthoxazine, spiro(benzindolin)naphthoxazine, spiro(indolin)naphthoxazine, spiro(indolin)pyrido-benzoxazine. Spiro(indoline)-benzoate, Spiro(benzindolin)-benzoate, Spiro(benzindolin)pyridobenzoate, Spiro(indoline)fluolanthenoxoate, Spiro(indoline)quinoxoate, Spiropiperidine-naphtopyran, Pyro(indoline)pyronobenzoate, Benzospiropyran, Naphtospiropyran, Spirobenzoate-pyrrolopyridine, Spironaphtok-pyrrolopyridine, Spiro-oxazepine-benzoate, Spiro(indoline)benzophyrroloxoate, Spiro(indoline)quinazolino-oxoate, Spiro(indoline)anthracenobenzoate, Benzofuro-benzopyran, Benzothienobenzopyran, These include naphthofurobenzopyran, benzopyrano-fused naphthofyran, spiro(isoindoline)-naphtoxase, spiro(isoindoline)benzoxase, etc. These photochromic compounds are U.S. Patents No. 3100778, No. 3562172, No. 3567605, No. 3578602, No. 3671543, No. 4215010, No. 4342668, No. 4440672, No. 4634767, No. 4636561, No. 4637698, No. 4699473, No. 4719296, No. 4720547, No. 4772700, No. 4784474, No. 4785097, No. 4816584, No. 4818096,No. 4826977, No. 4831142, No. 4880667, No. 4929693, No. 4931219, No. 4931221, No. 4959471, No. 4980089, No. 4986934, No. 5055576, No. 5066818, No. 5110922, No. 5114621, No. 5139707, No. 5166345, No. 5171636, No. 5180524, No. 5186867, No. 5200116, No. 5238931, No. 5238981, No. 5244602, No. 5274132, No. 5340857, No. 5369158, No. 5384077, No. 5395567, No. 5399687, No. 5405958, No. 5411679, No. 5429774, No. 5451344, No. 5458814, No. 5458815, No. 5464567, No. 5466398, No. 5514817, No. 5520853, No. 5552090, No. 5552091, No. 5565147, No. 5573712, No. 5578252, No. 5585042, No. 5623005, No. 5637262, No. 5637709, No. 5645767, No. 5650098, No. 5651923, No. 5656206, No. 5658500, No. 5658501, No. 5674432, No. 5698141, No. 5723072, No. 5728758, No. 5730908, No. 5744070, No. 5759450, No. 5783116, No. 5801243, No. 5808063, No. 5811034, No. 5831090, No. 5833885, No. 5869658, No. 5879592, No. 5891368, No. 5955520, No. 5961892, No. 5981634, No. 5998520, No. 6004486, No. 6017121, No. 6018059, No. 6019914, No. 6022495, No. 6022497, No. 6030555, No. 6034193, No. 6065836, No. 6106744, No. 6106744, No. 6107395, No. 6113814, No. 6146554, No. 6149841, No. 6153126, No. 6221284, No. 6248264,No. 6296785, No. 6315928, No. 6342459, No. 6348604, No. 6353102, No. 6414057, No. 6478988, No. 6630597, No. 7556750, No. 7584630, No. 7999989, No. 8158037, No. 8697770, No. 8698117, No. 8741188, No. 9029532, No. 9028728, No. 9052438, No. 9097916, No. 9465234, No. 9487499, No. 9904074, No. 10197707, No. 10501446, Disclosed in Patent No. 10532997 and No. 10502998, and also described in the literature [Techniques in Chemistry, Volume III. “Photochromism”, Chapter 3 (Glenn H. Brown, Editor, John Wiley and Sons, Inc., New York, 1971) and “Chromic Phenomena: Technological Applications of Colour Chemistry” (P. Bamfield, RSC Books (2001)). Derivatives of these compounds containing various substituents can be synthesized from this teaching by those skilled in the art.
[0124] The photochromic vinyl monomer, under well-known coupling reaction conditions, in the absence or presence of a coupling agent (i.e., having two of the reactive functional groups listed above), has a first reactive functional group (-COCl, -COBr, -COOH, -NHR). N2 , -NCO, -OH, -CHO, , , or , where R0 is hydrogen or methyl and R N2 is hydrogen, linear or branched C1-C 15A reactive (meth)acrylamido or (meth)acryloxy monomer having an alkyl, cyclohexyl, cyclopentyl, substituted or unsubstituted phenyl, or substituted or unsubstituted phenyl-C1-C6 alkyl group, and a second reactive functional group (-COOH, -NHR). N2 , , , , -NCO, -OH, -SH, -CHO, , , or It can be obtained by reacting with a reactive photochromic compound having ) to form a photochromic compound.
[0125] Preferably, non-limiting examples of coupling reactions under various reaction conditions between a pair of matching co-reactive functional groups selected from the group consisting of a primary group, a secondary amino group, a hydroxyl group, a carboxyl group, an acid halide group (-COX, X=Cl, Br, or I), an acid anhydride group, an aldehyde group, an isocyanate group, an epoxy group, an aziridine group, an azlactone group, and a thiol group are provided below for exemplary purposes. The primary / secondary amino group reacts with an aldehyde or ketone group to form a Schiff base that can be further reduced to an amine bond; the primary / secondary amino group -NHR (where R is hydrogen or a C1-C6 alkyl) reacts with an acid chloride or bromide group or with an acid anhydride group to form an amide linkage (-CO-NR-); the amino group -NHR reacts with an N-hydroxysuccinimide ester group to form an amide linkage; The amino group -NHR reacts with a carboxylic acid group in the presence of a coupling agent - carbodiimide (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N'-dicyclohexylcarbodiimide (DCC), 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide, diisopropylcarbodiimide, or a mixture thereof) and N-hydroxysuccinimide to form an amide linkage; the amino group -NHR reacts with an azlactone group (ring-opening) to form an alkylene-diamido linkage (-CONH-CR1 R 2 -(CH2) p1 -CONH-) forms; the amino group -NHR reacts with the isocyanate group to form a urea link (-NRo-C(O)-NH-(Ro is as defined above)); the amino group -NHR reacts with the epoxy or aziridine group to form an amine link (-C-NR-); the hydroxyl group reacts with the isocyanate to form a urethane link; the hydroxyl group reacts with the epoxy or aziridine to form an ether link (-O-); the hydroxyl group reacts with the acid chloride or bromide group or with the acid anhydride group to form an ester link; the carboxyl group reacts with the epoxy group to form an ester link; the thiol group (-SH) reacts with the isocyanate to form a thiocarbamate link (-NC(O)-S-); the thiol group reacts with the epoxy or aziridine to form a thioether link (-S-); The thiol group reacts with acid chloride or bromide groups or with acid anhydride groups to form a thioester linkage; the thiol group reacts with azlactone groups in the presence of a catalyst to form a linkage (-CONH-CR 1 R 2 -(CH2) p1 -CO-S-) forms; the thiol group reacts with the vinylsulfonyl group based on the thiol-en "click" reaction under thiol-en reaction conditions to form the thioether link (-S-); and the thiol group reacts with the (meth)acryloyl group based on Michael Addition under appropriate reaction conditions to form the thioether link.
[0126] The reaction conditions for the aforementioned coupling reaction are taught in textbooks and are well known to those skilled in the art.
[0127] Any coupling agent having two reactive functional groups may be used in the coupling reaction. Coupling agents having two reactive functional groups may be as follows: diisocyanate compounds; di-acid halide compounds; di-carboxylic acid compounds; di-carboxylic acid anhydride compounds; diamine compounds; diol compounds; di-epoxy compounds; di-aziridine compounds; di-azlactone compounds; di-ene compounds; divinylsulfone compounds; di-thiol compounds; thiolactone compounds; amino acid compounds; hydroxy-containing amine compounds; amine compounds having one hydroxyl or ketone group; hydroxy-containing carboxylic acid compounds; mercaptans having a hydroxyl, carboxyl, or amino group.
[0128] For example, diisocyanate, dicarboxylic acid (preferably dicarboxylic acid anhydride), diaziridine, diepoxy, or diazolactone compounds may be used for coupling the first and second reactive functional groups (where different or identical) and are selected from the group consisting of hydroxyl, primary amino, secondary amino, and thiol groups; diamine, dihydroxyl, dithiol, hydroxy-containing amine, or hydroxy-containing thiol compounds may be used for coupling the first and second reactive functional groups (where different or identical) and are selected from the group consisting of isocyanate, epoxy, aziridine, and carboxylic acid groups; and diepoxy compounds may be used for coupling the first and second reactive functional groups (where both are carboxylic acid groups); Diamine compounds may be used for coupling the first and second reactive functional groups (where both are aldehyde groups). Those skilled in the art are well aware of a method for forming the photochromic polydioganosiloxane vinyl crosslinker of the present invention by selecting one or more coupling agents based on the selectivity and / or differential reactivity of the specified reactive functional groups to link the first and second reactive functional groups.
[0129] Examples of commercially available dicarboxylic acid anhydrides include, without limitation, succinic anhydride, methyl succinic anhydride, 2,2-dimethyl succinic anhydride, 2,3-dimethyl succinic anhydride, glutaric anhydride, 3,3-dimethyl glutaric anhydride, 2,2-dimethyl glutaric anhydride, 3-methyl glutaric anhydride, 3,3-tetramethyl glutaric anhydride, diglycolic anhydride, adipic anhydride, etc.
[0130] Any suitable C3-C 24 Dicarboxylic acid compounds may be used in the present invention. Preferred examples of dicarboxylic acid compounds include, without limitation, linear or branched C3-C24 aliphatic dicarboxylic acids, C5-C 24 cycloaliphatic or aliphatic-cycloaliphatic dicarboxylic acid, C6-C 24 Includes aromatic or ar aliphatic dicarboxylic acids, dicarboxylic acids containing an amino or imido group or an N-heterocyclic ring, and combinations thereof. Examples of suitable aliphatic dicarboxylic acids are as follows: oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, souveric acid, azelaic acid, sebacic acid, undecandioic acid, dodecandioic acid, dimethylmalonic acid, octadecyl succinic acid, trimethyladipic acid, and dimeric acids (dimerization products of unsaturated aliphatic carboxylic acids such as oleic acid). Examples of suitable cycloaliphatic dicarboxylic acids are as follows: 1,3-cyclobutanedicarboxylic acid, 1,3-cyclopentanedicarboxylic acid, 1,3- and 1,4-cyclohexanedicarboxylic acid, 1,3- and 1,4-dicarboxymethylcyclohexane, 4,4'-dicyclohexyldicarboxylic acid. Examples of suitable aromatic dicarboxylic acids are as follows: terephthalic acid, isophthalic acid, o-phthalic acid, 1,3-, 1,4-, 2,6-, or 2,7-naphthalenedicarboxylic acid, 4,4'-biphenyldicarboxylic acid, 2,2'-biphenyl-dicarboxylic acid, 4,4'-diphenylsulfone-dicarboxylic acid, 1,1,3-trimethyl-5-carboxyl-3-(p-carboxyphenyl)-indane, 4,4'-diphenyl ether-dicarboxylic acid, bis-p-(carboxyphenyl)-methane.
[0131] Any suitable diacid halide may be used in the present invention. Preferred examples of diacid halides include, but are not limited to, fumaryl chloride, suberoyl chloride, succinyl chloride, phthaloyl chloride, isophthaloyl chloride, terephthaloyl chloride, sebacoyl chloride, adipoyl chloride, trimethyladipoyl chloride, azelaoil chloride, dodecandioic acid chloride, succin chloride, glutaric acid chloride, oxalyl chloride, dimeric acid chlorides, and combinations thereof.
[0132] Any suitable diamine may be used in the present invention. Organic diamines are linear or branched C2-C 24 Aliphatic diamine, C5-C 24 cycloaliphatic or aliphatic cycloaliphatic diamines, or C6-C 24It may be an aromatic or alkyl-aromatic diamine. Preferred organic diamines are N,N'-bis(hydroxyethyl)ethylenediamine, N,N'-dimethylethylenediamine, ethylenediamine, N,N'-dimethyl-1,3-propanediamine, N,N'-diethyl-1,3-propanediamine, N-methyl-1,3-diaminopropane, N-methylethylenediamine, N-ethylethylenediamine, N-isopropyl-1,3-propanediamine, N-propyl-1,3-propanediamine, N-butylethylenediamine, 2,2-dimethyl-1,3-propanediamine, 1,4-butanediamine, 1,5-pentanediamine, hexamethylenediamine, 2-methyl-1,5-pentanediamine, 1,6-hexamethylenediamine, N,N'-dimethyl-1,6-hexamethylenediamine, 2, 2,4(2,4,4)-trimethyl-1,6-hexanediamine, 1,3-diamino-2-propanol, 1,2-diaminoethane-1,2-diol, 1,1-diaminoethane-1,2-diol, 1,4-diamino-2,3-butanediol, 1,3-cyclopentanediamine, 1,4-diaminocyclohexane, 1,3-bis(aminomethyl)cyclohexane, 4,4'-diaminodicyclohexylmethane, 4,4'-methylenebis(2-methylcyclohexylamine), isophorone diamine (3-aminomethyl-3,5,5-trimethylcyclohexylamine), m-xylylene diamine, p-xylylene diamine, piperazine, 1-(2-aminoethyl)piperazine, 1,4-bis(3-aminopropyl)piperazine, These include 2-piperazinoethylamine, 1-Boc-piperazine, 4-(2-aminoethyl)-1-Boc-piperazine, 1-(2-N-Boc-aminoethyl)piperazine, 4-(2-aminoethyl)-1-Boc-piperazine, 4-aminopiperidine, 3-aminopiperidine, 4-aminomethylpiperidine, 2-aminomethylpiperidine, 1-Boc-piperidine-4-carboxaldehyde, 1-Boc-piperidine-4-acetaldehyde, etc.
[0133] Any suitable C4-C 24Diisocyanates may be used in the present invention. Preferred examples of diisocyanates include, without limitation, tetramethylene diisocyanate, pentamethylene diisocyanate, hexamethylene diisocyanate, heptamethylene diisocyanate, 1,6-diisocyanato-2,2,4-trimethylhexane, octamethylene diisocyanate, dodecamethylene diisocyanate, cyclohexane diisocyanate, 1,3-bis-(4,4'-isocyanotomethyl)cyclohexane, isophorone diisocyanate, 4,4'-dicyclohexylmethane diisocyanate, toluene diisocyanate, 4,4'-diphenyl diisocyanate, 4,4'-diphenylmethane diisocyanate, p-phenylene isocyanate, etc.
[0134] Any suitable di-epoxy compound may be used in the present invention. Examples of preferred di-epoxy compounds include neopentyl glycol diglycidyl ether, 1,3-butadiene diepoxide, 1,4-butanediol diglycidyl ether, 1,2,7,8-diepoxyoctane, 3,4-epoxycyclohexylmethyl-3,4-epoxy-cyclohexane, 3,4-epoxycyclohexylmethyl-3,4-epoxycyclohexane carboxylate, vinylcyclohexene dioxide, 1,6-hexanediol diglycidyl ether, glycerol diglycidyl ether, ethylene glycol diglycidyl ether, diethylene glycol diglycidyl ether, polyethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, dipropylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether, There are bis[4-(glycidyloxy)phenyl]methane, bisphenol A diglycidyl ether (2,2-bis[4-(glycidyloxy)phenyl]-propane), bisphenol A propoxylate diglycidyl ether, and combinations thereof.
[0135] Any suitable C2-C 24Diols (i.e., compounds having two hydroxyl groups) may be used in the present invention. Preferred examples of diols include, without limitation, ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, propylene glycol, 1,4-butanediol, various pentanediols, various hexanediols, various cyclohexanediols, 1,4-bis(2-hydroxyethyl)piperazine, bisphenol A, bisphenol F, 4,4'-methylenediphenol, and combinations thereof.
[0136] Any amino acid may be used in the present invention. Examples of amino acids include, without limitation, glycine, proline, alanine, valine, isoleucine, leucine, 2-aminoisobutyric acid, 4-aminobutyric acid, 3-aminoisobutyric acid, 3-amino-butyric acid, β-alanine, 1-amino-3-cyclopentane carboxylic acid, 3-aminocyclohexane carboxylic acid, pyrrolidine-3-carboxylic acid, 4-piperidine carboxylic acid, 3-piperidine carboxylic acid, 1-piperazine acetic acid, etc.
[0137] Examples of compounds having one amino group and one hydroxyl or aldehyde group (or ketone group) are, without limitation, 1-piperazinepropanol, 2-[2-(1-piperazinyl)ethoxy]-ethanol, 4-amino-1-piperazineethanol, 4-amino-1-piperazineethanol, piperidinemethanol, 1-Boc-piperidin-4-carboxaldehyde, 4-formylpiperidin, N-Boc-4-piperidinacetaldehyde, etc.
[0138] Desirable reactive (meth)acrylamido or (meth)acryloxy monomers include, without limitation, those described below in this application.
[0139] Desired photochromic compounds include, without limitation, compounds that can be obtained from commercial suppliers described below in this application or can be manufactured according to the patent discussed above and the procedures described in the text above.
[0140] Lens molds for manufacturing contact lenses, including hydrogel contact lenses, are well known to those skilled in the art and are used, for example, in cast molding or spin casting. For example, a mold (for cast molding) generally comprises at least two mold sections (or parts) or mold halves, namely a first and a second mold halve. The first mold halve defines a first molding (or optical) surface and the second mold halve defines a second molding (or optical) surface. The first and second mold halves are configured to receive each other to form a lens-forming cavity between the first molding surface and the second molding surface. The molding surface of the mold halve is the cavity-forming surface of the mold and is in direct contact with the polymerizable composition.
[0141] Methods for manufacturing mold sections for casting contact lenses are generally well known to those skilled in the art. The method of the present invention is not limited to any specific mold forming method. In fact, any mold forming method may be used in the present invention.
[0142] Generally, the mold consists of at least two mold halves (or mold sections), one male mold half and one female mold half. The male mold half has a first molding (or optical) surface that is in direct contact with the polymerizable composition for casting a contact lens and defines the rear (concave) surface of the molded contact lens; the female mold half has a second molding (or optical) surface that is in direct contact with the polymerizable composition and defines the front (convex) surface of the molded contact lens. The male and female mold halves are configured to receive each other to form a lens forming cavity between the first molding surface and the second molding surface.
[0143] Mold half can be formed through various techniques such as injection molding. Methods for manufacturing mold half for cast-molding contact lenses are generally well known to those skilled in the art. The method of the present invention is not limited to any specific mold forming method. In fact, any mold forming method may be used in the present invention. The first and second mold half can be formed through various techniques such as injection molding or lathes. Examples of processes suitable for forming mold half are disclosed in U.S. Patents No. 4444711; No. 4460534; No. 5843346; and No. 5894002.
[0144] Almost all materials known in the art for mold manufacturing can be used to manufacture molds for contact lens manufacturing. For example, polymeric materials, such as polyethylene, polypropylene, polystyrene, PMMA, and Topas ® COC grade 8007-S10 (a transparent amorphous copolymer of ethylene and norbornene from Ticona GmbH in Frankfurt, Germany and Summit in New Jersey, USA) may be used. Other materials that allow UV light transmission, such as quartz glass and sapphire, may be used.
[0145] According to the present invention, the first or second polymerizable fluid composition can be distributed onto the molding surface of a female mold half according to any known technique.
[0146] A specific amount of the first polymerizable fluid composition is generally distributed into the female mold half by a dispensing device, then the male mold half is raised and the mold is closed. As the mold is closed, the excess first polymerizable fluid composition is compressed into an overflow provided in the female mold half (or alternatively the male mold half).
[0147] Next, UV or visible light is irradiated (i.e., cured or polymerized) as is known to those skilled in the art onto a molded assembly (i.e., a closed mold containing a first polymerizable fluid composition and a partially crosslinked circular layer immersed therein) to produce a molded, unprocessed hydrogel contact lens.
[0148] When the first or second polymerizable fluid composition comprises at least one member selected from the group consisting of UV-absorbing vinyl monomers, polymerizable UV / HEVL-absorbing compounds, photochromic compounds, and fluorescent compounds, the free radical initiator is preferably a visible light photoinitiator (e.g., benzoylphosphine initiator and / or acylgermanium photoinitiator), and crosslinking is initiated upon exposure to visible light in the 420 nm to 500 nm range to crosslink the polymerizable components in the first polymerizable fluid composition to form a molded unprocessed contact lens. The light source may emit light in the 420 to 500 nm range sufficient to activate the acylgermanium photoinitiator. Blue light sources are commercially available and include: the Palatray Cu Blue-Light Unit (available from Heraeus Kulzer, Inc., Irvine, Calif.), the Fusion F450 blue light system (available from TEAMCO, Richardson, Tex.), the Dymax Blue Wave 200, LED light sources from Opsytec (435 nm, 445 nm, 460 nm), and GE 24" blue fluorescent lamps (available from General Electric Company, US). A preferred blue light source is an Opsytec LED (as described above).
[0149] After curing, the mold can also be opened according to any technique known to those skilled in the art. After the mold is separated, the molded raw hydrogel contact lens is attached to one of the female mold halves.
[0150] An unprocessed hydrogel contact lens attached to a lens-attached mold half may undergo one or more post-molding processes after being removed from the lens-attached mold half.
[0151] For example, an unprocessed hydrogel contact lens can be extracted with a liquid extraction medium to remove unpolymerized polymerizable components and formed oligomers. According to the present invention, the extraction liquid medium is an organic solvent, any solvent capable of dissolving unpolymerized polymerizable material and oligomers in a dry contact lens. Water, any organic solvent known to those skilled in the art, or a mixture thereof may be used in the present invention. Preferably, the organic solvent as the extraction liquid medium is water, buffered brine, C1-C3 alkyl alcohol, 1,2-propylene glycol, polyethylene glycol having a number average molecular weight of about 400 daltons or less, C1-C6 alkyl alcohol, or a combination thereof.
[0152] The hydrogel contact lens may also be surface treated at 18 to 124°C for at least 30 minutes (e.g., plasma treatment, chemical treatment, grafting of hydrophilic monomers or macromonomers on the lens surface, layer-by-layer coating, in-package crosslinking of a thermally reactive hydrophilic polymer material, etc.); packaged in a lens package with a packaging solution that may contain about 0.005 wt% to about 5 wt% of a wetting agent (e.g., hydrophilic polymer), a viscosity enhancer (e.g., methylcellulose (MC), ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), or a mixture thereof), or an in-package coating material; and may undergo additional processes such as sterilization, such as autoclave.
[0153] Preferred surface treatments include LbL coatings as disclosed in U.S. Patents No. 6451871, 6719929, 6793973, 6811805, and 6896926, plasma treatment, and in-package coatings as disclosed in U.S. Patents No. 8557334, 8529057, and 9505184. Preferred plasma treatment is a process in which an ionized gas is applied to the surface of an article as described in U.S. Patents No. 4312575 and 4632844.
[0154] Hydrogel contact lenses are hydrated in water or an aqueous solution to replace the liquid extraction medium according to any method known to those skilled in the art.
[0155] Hydrated and / or surface-treated photochromic contact lenses may undergo additional processes such as packaging within a lens package having a packaging solution well known to those skilled in the art, for example; sterilization such as autoclaving at 118 to 124°C for about 30 minutes or more.
[0156] Lens packages (or containers) for autoclaving and storing soft contact lenses are well known to those skilled in the art. Any lens package may be used in the present invention. Preferably, the lens package is a blister package comprising a base and a cover, the cover being removablely sealed to the base, and the base comprising a cavity for receiving a sterile packaging solution and a contact lens.
[0157] Lenses are packaged into individual packages, sealed, and sterilized (e.g., by autoclave at about 120°C or higher under pressure for at least 30 minutes) before being distributed to users. Those skilled in the art will understand well how to seal and sterilize lens packages.
[0158] The oxygen permeability of the SiHy contact lens of the present invention is preferably about 40 barrer or more, more preferably about 60 barrer or more, and even more preferably about 80 barrer or more (at about 35°C).
[0159] The elastic modulus of the hydrogel contact lens of the present invention is about 1.5 MPa or less, preferably about 1.2 MPa or less, more preferably about 0.3 MPa to about 1.0 MPa (at a temperature of about 22°C to 28°C).
[0160] The hydrogel contact lens of the present invention further has an equilibrium water content of about 15% to about 75% (at room temperature) when fully hydrated, more preferably about 20% to about 70 wt%, and more preferably about 25% to about 65 wt%. The equilibrium water content of the photochromic contact lens can be measured according to the procedure disclosed in Example 1.
[0161] In a further embodiment, the present invention provides a hydrogel contact lens obtained according to the method of the present invention.
[0162] All various embodiments of the mold, polymerizable composition, radiation spatial limitation, and contact lens of the present invention described above may be used in this aspect of the present invention.
[0163] Although various embodiments of the present invention have been described using specific terms, devices, and methods, such description is for illustrative purposes only. The words used are descriptive, not limiting. It should be understood that modifications and variations may be made by those skilled in the art without departing from the spirit or scope of the invention as set forth in the following claims. Furthermore, it should be understood that aspects of various embodiments may be interchangeable in whole or in part, or may be combined and / or used together in any manner as exemplified below:
[0164] 1. A method for manufacturing a hydrogel contact lens,
[0165] (1) A step of obtaining a first polymerizable fluid composition and a second polymerizable fluid composition (the first polymerizable fluid composition comprises at least one photoinitiator and at least one polymerizable material and is free of any photochemical functional compounds, and the second polymerizable fluid composition comprises the at least one photoinitiator and the at least one polymerizable material and additionally at least one photochemical functional compound, and the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable fluid composition and the second polymerizable fluid composition is about 5.0% or less, and the at least one photochemical functional compound is at least one photochromic compound, at least one UV / HEVL absorbing compound, at least one fluorescent compound, at least one color-filtering material for colorblind correction, at least one diffracting material, at least one high refractive index material, or a combination thereof, the first polymerizable fluid composition has a first curing time and the second polymerizable fluid composition has a second curing time, and the first and second curing times are measured in a photorheological study using UV / visible light of a specific intensity);
[0166] (2) A step of obtaining a lens mold comprising a female mold half having a first molding surface defining the front surface of a contact lens to be molded and a male mold half having a second molding surface defining the rear surface of a contact lens to be molded, wherein the female and male mold halves receive each other when the mold is closed to form a mold cavity between the first and second molding surfaces;
[0167] (3) A step of applying a predetermined amount of the second polymerizable fluid composition onto the central area of the first molding part of the female mold half to form a circular layer of the second polymerizable fluid composition (the diameter of the circular layer is about 13.00 mm or less);
[0168] (4) A step of partially crosslinking the original layer of the second polymerizable fluid composition by irradiating it with UV / visible light of a specific intensity for about 5% to about 75% of the second curing time;
[0169] (5) A step of distributing a predetermined amount of a first polymerizable fluid composition onto a partially cross-linked circular layer on the central region of the first molding surface;
[0170] (6) A step of forming a molded assembly comprising a partially cross-linked circular layer immersed in a first polymerizable fluid composition within a mold cavity by closing the female mold half with the male mold half;
[0171] (7) A step of forming a raw hydrogel contact lens having a central region by irradiating a molded assembly with UV / visible light of a specific intensity for at least about 120% of the first curing time, wherein the central region is concentric with the central axis of the raw hydrogel contact lens, has a diameter of about 13 mm or less, and has at least one photochemical functionality provided by the at least one photochemical functional compound;
[0172] (8) A step of separating the molded assembly into a male mold half and a female mold half with an unprocessed hydrogel contact lens attached to one of the male and female mold halfs;
[0173] (9) a step of removing the unprocessed hydrogel contact lens from the lens-attached mold half; and
[0174] (10) A step of applying an unprocessed hydrogel contact lens to a post-molding process comprising a hydration process and one or more other processes selected from the group consisting of extraction, surface treatment, packaging, sterilization, and combinations thereof.
[0175] A method including
[0176] 2. A method according to Embodiment 1, wherein the first and second polymerizable fluid compositions can form a non-silicon hydrogel, and the at least one polymerizable material is a first monomer mixture comprising (a) at least one first hydrophilic vinyl monomer and (b) at least one component selected from the group consisting of at least one non-silicon vinyl crosslinking agent, a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof.
[0177] 3. A method according to Embodiment 2, wherein the at least one first hydrophilic vinyl monomer comprises at least one hydroxyl-containing vinyl monomer, N,N-dimethylarylamide, N-vinylpyrrolidone, at least one methylene-containing pyrrolidone monomer, or a combination thereof.
[0178] 4. A method according to Embodiment 2 or Embodiment 3, wherein the at least one polymerizable material comprises at least 50% by weight of at least one hydroxyl-containing vinyl monomer relative to the total weight of all polymerizable materials present in the first polymerizable fluid composition.
[0179] 5. A method according to Embodiment 2 or Embodiment 3, wherein the at least one polymerizable material comprises at least 55% by weight of at least one hydroxyl-containing vinyl monomer relative to the total weight of all polymerizable materials present in the first polymerizable fluid composition.
[0180] 6. A method according to Embodiment 2 or Embodiment 3, wherein the at least one polymerizable material comprises at least 60 weight% of at least one hydroxyl-containing vinyl monomer relative to the total weight of all polymerizable materials present in the first polymerizable fluid composition.
[0181] 7. A method according to Embodiment 2 or Embodiment 3, wherein the at least one polymerizable material comprises at least 65% by weight of at least one hydroxyl-containing vinyl monomer relative to the total weight of all polymerizable materials present in the first polymerizable fluid composition.
[0182] 8. In any one of embodiments 3 to 7, the at least one hydroxyl-containing vinyl monomer is 2-hydroxyethyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, glycerol methacrylate (GMA), di(ethylene glycol) (meth)acrylate, tri(ethylene glycol) (meth)acrylate, tetra(ethylene glycol) (meth)acrylate, poly(ethylene glycol) (meth)acrylate having a number average molecular weight of up to 1500, trimethylammonium 2-hydroxypropyl (meth)acrylate hydrochloride, N-2-hydroxyethyl (meth)acrylamide, N-3-hydroxypropyl (meth)acrylamide, N-2-hydroxypropyl (meth)acrylamide, N-2,3-dihydroxypropyl (meth)acrylamide, N-4-hydroxybutyl (meth)acrylamide, N,N-bis(2-hydroxyethyl) (meth)acrylamide, N - A method selected from the group consisting of tris(hydroxymethyl)methyl (meth)acrylamide, N-2-hydroxyethyl vinyl carbamate, and combinations thereof.
[0183] 9. A method in any one of embodiments 3 to 7, wherein the at least one hydroxyl-containing vinyl monomer is selected from the group consisting of hydroxyethyl (meth)acrylate, glycerol (meth)acrylate, N-2-hydroxyethyl (meth)acrylamide, N-3-hydroxypropyl (meth)acrylamide, N-2-hydroxypropyl (meth)acrylamide, N-2,3-dihydroxypropyl (meth)acrylamide, di(ethylene glycol) (meth)acrylate, N-2-hydroxyethyl vinyl carbamate, and combinations thereof.
[0184] 10. A method in any one of embodiments 3 to 7, wherein the at least one hydroxyl-containing vinyl monomer is selected from the group consisting of hydroxyethyl (meth)acrylate, glycerol (meth)acrylate, N-2-hydroxyethyl (meth)acrylamide, and combinations thereof.
[0185] 11. A method according to Embodiment 1, wherein the first and second polymerizable fluid compositions can form a non-silicon hydrogel, and the at least one polymerizable material is a reactive mixture comprising (a) one or more water-soluble non-silicon prepolymers and optionally (b) at least one component selected from the group consisting of a hydrophilic vinyl monomer, a non-silicon vinyl crosslinking agent, a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof.
[0186] 12. In Embodiment 11, one or more water-soluble non-silicon prepolymers are each (a1) 60 mol% or more The repeating unit of and (a2) A water-soluble chemical-crosslinkable poly(vinyl alcohol) prepolymer comprising repeating units, wherein R3 and R5 are independently H or C1-C4 alkyl; R4 is a C1-C4 alkylene divalent radical; and R6 is a monovalent organic radical having an acrylic group.
[0187] 13. A method according to Embodiment 1, wherein the first and second polymerizable fluid compositions can form a silicon hydrogel, and the at least one polymerizable material is a second monomer mixture comprising at least one component selected from the group consisting of (a) at least one silicon-containing vinyl monomer, (b) at least one polysiloxane vinyl crosslinker, at least one non-silicon vinyl crosslinker, or both, (c) at least one second hydrophilic vinyl monomer, and optionally (d) a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof.
[0188] 14. A method according to Embodiment 13, wherein the at least one second hydrophilic vinyl monomer comprises at least one hydrophilic (meth)acrylamido monomer.
[0189] 15. In Embodiment 14, the method wherein at least one hydrophilic (meth)acrylamido monomer has 3 to 8 carbon atoms with respect to the total weight of the polymerizable composition.
[0190] 16. In Embodiment 14, the at least one hydrophilic (meth)acrylamido monomer is (meth)acrylamide, N-methyl (meth)acrylamide, N,N-dimethyl (meth)acrylamide, N-ethyl (meth)acrylamide, N,N-diethyl (meth)acrylamide, N-propyl (meth)acrylamide, N-isopropyl (meth)acrylamide, N-3-methoxypropyl (meth)acrylamide, N-2-hydroxyethyl (meth)acrylamide, N-3-hydroxypropyl (meth)acrylamide, N-2-hydroxypropyl (meth)acrylamide, N-2,3-dihydroxypropyl (meth)acrylamide, N-4-hydroxybutyl (meth)acrylamide, N,N-bis(2-hydroxyethyl) (meth)acrylamide, N-Tris(hydroxymethyl)methyl(meth)acrylamide, 2-(meth)acrylamido-glycolic acid, 3-(meth)acrylamidopropionic acid, 4-(meth)acrylamido-butanoic acid, 3-(meth)acrylamido-2-methylbutanoic acid, 3-(meth)acrylamido-3-methylbutanoic acid, 2-(meth)acrylamido-2-methyl-3,3-dimethylbutanoic acid, 5-(meth)acrylamidopentanoic acid, 3-(meth)acrylamidohexanoic acid, 4-(meth)acrylamido-3,3-dimethylhexanoic acid, (3-(meth)acrylamidophenyl)boronic acid, 3-((3-methacrylamidopropyl)dimethylammonio)-propane-1-sulfonate; A method selected from the group consisting of 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate, poly(ethylene glycol)ethyl (meth)acrylamide having a number average molecular weight of up to 700, methoxy-poly(ethylene glycol)ethyl (meth)acrylamide having a number average molecular weight of up to 700, and combinations thereof.
[0191] 17. A method in any one of embodiments 14 to 16, wherein the at least one hydrophilic (meth)acrylamido monomer comprises N,N-dimethyl (meth)acrylamide, N-ethyl (meth)acrylamide, N-2-hydroxyethyl (meth)acrylamide, N-3-hydroxypropyl (meth)acrylamide, N-2-hydroxypropyl (meth)acrylamide, N-2,3-dihydroxypropyl (meth)acrylamide, (meth)acrylamide, or a combination thereof.
[0192] 18. A method in any one of embodiments 14 to 16, wherein the at least one hydrophilic (meth)acrylamido monomer comprises N,N-dimethyl (meth)acrylamide, N-2-hydroxyethyl (meth)acrylamide, or a combination thereof.
[0193] 19. A method in any one of embodiments 13 to 18, wherein the at least one second hydrophilic vinyl monomer comprises at least one hydrophilic (meth)acryloxy monomer.
[0194] 20. In Embodiment 19, the at least one second hydrophilic (meth)acryloxy monomer is 2-hydroxyethyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, glycerol methacrylate (GMA), di(ethylene glycol) (meth)acrylate, tri(ethylene glycol) (meth)acrylate, tetra(ethylene glycol) (meth)acrylate, poly(ethylene glycol) (meth)acrylate having a number average molecular weight of up to 1500, (meth)acrylic acid, ethyl acrylic acid, propyl acrylic acid, butyl acrylic acid, trimethylammonium 2-hydroxypropyl (meth)acrylate hydrochloride, dimethylaminoethyl (meth)acrylate, ethylene glycol methyl ether (meth)acrylate, di(ethylene glycol) methyl ether A method selected from the group consisting of (meth)acrylate, tri(ethylene glycol) methyl ether (meth)acrylate, tetra(ethylene glycol) methyl ether (meth)acrylate, C1-C4-alkoxy poly(ethylene glycol) (meth)acrylate having a number average molecular weight of up to 1500, and combinations thereof.
[0195] 21. In any one of embodiments 13 to 20, the at least one second hydrophilic vinyl monomer is N-vinylpyrrolidone, N-vinyl-3-methyl-2-pyrrolidone, N-vinyl-4-methyl-2-pyrrolidone, N-vinyl-5-methyl-2-pyrrolidone, N-vinyl-6-methyl-2-pyrrolidone, N-vinyl-3-ethyl-2-pyrrolidone, N-vinyl-4,5-dimethyl-2-pyrrolidone, N-vinyl-5,5-dimethyl-2-pyrrolidone, N-vinyl-3,3,5-trimethyl-2-pyrrolidone, N-vinylpiperidone ( life , N-vinyl-2-piperidone), N-vinyl-3-methyl-2-piperidone, N-vinyl-4-methyl-2-piperidone, N-vinyl-5-methyl-2-piperidone, N-vinyl-6-methyl-2-piperidone, N-vinyl-6-ethyl-2-piperidone, N-vinyl-3,5-dimethyl-2-piperidone, N-vinyl-4,4-dimethyl-2-piperidone, N-vinyl caprolactam( lifeA method comprising at least one hydrophilic N-vinylamide monomer selected from the group consisting of N-vinyl-2-caprolactam), N-vinyl-3-methyl-2-caprolactam, N-vinyl-4-methyl-2-caprolactam, N-vinyl-7-methyl-2-caprolactam, N-vinyl-7-ethyl-2-caprolactam, N-vinyl-3,5-dimethyl-2-caprolactam, N-vinyl-4,6-dimethyl-2-caprolactam, N-vinyl-3,5,7-trimethyl-2-caprolactam, N-vinyl-N-methylacetamide, N-vinyl formamide, N-vinyl acetamide, N-vinyl isopropylamide, N-vinyl-N-ethylacetamide, N-vinyl-N-ethylformamide, and mixtures thereof.
[0196] 22. A method in any one of embodiments 13 to 20, wherein the at least one second hydrophilic vinyl monomer comprises N-vinylpyrrolidone and / or N-vinyl-N-methylacetamide.
[0197] 23. In any one of embodiments 13 to 22, the at least one second hydrophilic vinyl monomer is (a) 1-methyl-3-methylene-2-pyrrolidone, 1-ethyl-3-methylene-2-pyrrolidone, 1-methyl-5-methylene-2-pyrrolidone-pyrrolidone, 1-ethyl-5-methylene-2-pyrrolidone, 5-methyl-3-methylene-2-pyrrolidone, 5-ethyl-3-methylene-2-pyrrolidone, 1-n-propyl-3-methylene-2-pyrrolidone, 1-n-propyl-5-methylene-2-pyrrolidone, 1-isopropyl-3-methylene-2-pyrrolidone, 1-isopropyl-5-methylene-2-pyrrolidone, 1-n-butyl-3-methylene-2-pyrrolidone, (b) at least one methylene-containing pyrrolidone monomer selected from the group consisting of 1-tert-butyl-3-methylene-2-pyrrolidone and combinations thereof; (b) at least one vinyl ether monomer selected from the group consisting of ethylene glycol monovinyl ether, di(ethylene glycol) monovinyl ether, tri(ethylene glycol) monovinyl ether, tetra(ethylene glycol) monovinyl ether, poly(ethylene glycol) monovinyl ether, ethylene glycol methyl vinyl ether, di(ethylene glycol) methyl vinyl ether, tri(ethylene glycol) methyl vinyl ether, tetra(ethylene glycol) methyl vinyl ether, poly(ethylene glycol) methyl vinyl ether, and combinations thereof; (c) at least one allyl ether monomer selected from the group consisting of ethylene glycol monoallyl ether, di(ethylene glycol) monoallyl ether, tri(ethylene glycol) monoallyl ether, tetra(ethylene glycol) monoallyl ether, poly(ethylene glycol) monoallyl ether, ethylene glycol methylallyl ether, di(ethylene glycol) methylallyl ether, tri(ethylene glycol) methylallyl ether, tetra(ethylene glycol) methylallyl ether, poly(ethylene glycol) methylallyl ether, and combinations thereof;(d) (meth)acryloyloxyethylphosphorylcholine, (meth)acryloyloxypropylphosphorylcholine, 4-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-[(meth)acryloylamino]-ethyl-2'-(trimethylammonio)-ethylphosphate, 3-[(meth)acryloylamino]propyl-2'-(trimethylammonio)ethylphosphate, 4-[(meth)acryloylamino]butyl-2'-(trimethylammonio)-ethylphosphate, 5-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethylphosphate, 6-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy)-ethyl-2'-(triethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(tripropylammonio)ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(tributylammonio)ethyl phosphate, 2-((meth)acryloyloxy)propyl-2'-(trimethylammonio)-ethyl phosphate, 2-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)-pentyl-2'-(trimethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)ethyl phosphate, At least one phosphorylcholine-containing vinyl monomer selected from the group consisting of 2-(vinyloxy)ethyl-2'-(trimethylammonio)-ethyl phosphate, 2-(allyloxy)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(vinyloxycarbonyl)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(allyloxycarbonyl)ethyl-2'-(trimethylammonio)-ethyl phosphate, 2-(vinylcarbonylamino)ethyl-2'-(trimethylammonio)-ethyl phosphate, 2-(allyloxycarbonylamino)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(butenoyloxy)ethyl-2'-(trimethylammonio)ethyl phosphate, and combinations thereof; (e) allyl alcohol; (f) N-2-hydroxyethyl vinyl carbamate; (g) N-vinyloxycarbonyl-β-alanine (VINAL); (h) N-vinyloxycarbonyl-α-alanine;or (i) a method comprising a combination of these.;
[0198] 24. A method in any one of embodiments 13 to 23, wherein the at least one silicon-containing vinyl monomer comprises at least one silicon-containing (meth)acrylamido monomer containing a tris(trialkylsiloxy)silyl group.
[0199] 25. In Embodiment 24, the at least one silicon-containing (meth)acrylamido monomer containing a tris(trialkylsiloxy)silyl group is N-[tris(trimethylsiloxy)silylpropyl] (meth)acrylamide, N-[tris(dimethylethylsiloxy)-silylpropyl] (meth)acrylamide, N-[tris(dimethylpropylsiloxy)silylpropyl] (meth)acrylamide, N-[tris(dimethylphenylsiloxy)silylpropyl] (meth)acrylamide, N-(2-hydroxy-3-(3-(tris(trimethyl)-silyloxy)silyl)propyloxy)propyl)-2-methyl (meth)acrylamide, N-(2-hydroxy-3-(3-(tris(trimethyl-silyloxy)silyl)propyloxy)propyl) (meth)acrylamide, N, A method selected from the group consisting of N-bis[2-hydroxy-3-(3-(tris(trimethyl-silyloxy)silyl)propyloxy)propyl]-2-methyl (meth)acrylamide, N,N-bis[2-hydroxy-3-(3-(tris(trimethylsilyloxy)silyl)propyloxy)propyl](meth)acrylamide, and combinations thereof.
[0200] 26. A method in any one of embodiments 13 to 25, wherein the at least one silicon-containing vinyl monomer comprises at least one silicon-containing (meth)acrylamido monomer containing a bis(trialkylsilyloxy)-alkylsilyl group.
[0201] 27. In Embodiment 26, the at least one silicon-containing (meth)acrylamido monomer containing a bis(trialkylsilyloxy)alkylsilyl group is N-(2-hydroxy-3-(3-(bis(trimethylsilyloxy)methylsilyl)propyloxy)propyl)-2-methyl (meth)acrylamide, N-(2-hydroxy-3-(3-(bis(trimethylsilyloxy)methylsilyl)propyloxy)-propyl) (meth)acrylamide, N,N-bis[2-hydroxy-3-(3-(bis(trimethylsilyloxy)methylsilyl)propyloxy)propyl]-2-methyl (meth)acrylamide, N,N-bis[2-hydroxy-3-(3-(bis(trimethylsilyloxy)methylsilyl)propyloxy)-propyl] (meth)acrylamide, Selected from the group consisting of N-[2-hydroxy-3-(3-(t-butyl-dimethylsilyl)propyloxy)propyl]-2-methylacrylamide, a siloxane-containing (meth)acrylamido monomer of one of the following chemical formulas Ia to Ih, and combinations thereof,
[0202] [Chemical Formula Ia]
[0203] ;
[0204] [Chemical Formula Ib]
[0205] ;
[0206] [Chemical Formula Ic]
[0207] ;
[0208] [Chemical Formula Id]
[0209] ;
[0210] [Chemical Formula Ie]
[0211] ;
[0212] [Chemical Formula If]
[0213] ;
[0214] [Chemical Formula Ig]
[0215] ;
[0216] [Chemical Formula Ih]
[0217] ,
[0218] In the above equation, R 13 -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, , , , , , , , , , or is a divalent alkylene radical, and R 14 is a divalent alkylene radical of -CH2CH2- or -CH2CH2CH2-, and R 15 Is or is a divalent alkylene radical, and R" and R 11 A method in which the groups are independently C1-C4 alkyls and f1 is an integer from 3 to 5.
[0219] 28. In any one of embodiments 13 to 27, the at least one silicon-containing vinyl monomer comprises at least one mono-(meth)acrylamido-terminated oligo- or polysiloxane of the following formula IIa, and
[0220] [Chemical Formula IIa]
[0221]
[0222] In the above formula, R' is hydrogen or methyl, R" is independently a C1-C6 alkyl, g1 and g2 are independently integers of 0 or 1, h1 is an integer from 2 to 25, and R9 and R 10 C1-C are independently substituted or non-substituted. 10 It is a divalent alkylene radical, and Y1 is , , or It is a connector of, and R 12 and R 12' is independently C1-C6 alkyl, method.
[0223] 29. A method according to Embodiment 28, wherein in Formula IIa, h1 is an integer from 3 to 20 (preferably from 3 to 15).
[0224] 30. In Embodiment 28 or Embodiment 29, in Formula IIa, R 12 and R 12 ' is independently methyl, method.
[0225] 31. In any one of embodiments 28 to 30, at least one mono-(meth)acrylamido-terminated oligo- or polysiloxane is α-(meth)acryloyl-amidopropyloxypropyl-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-N-methyl-(meth)acryloylamidopropyloxypropyl-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acrylamidoethoxy-2-hydroxypropyloxy-propyl]-terminated ω-C1-C4-alkyl polydimethylsiloxane, α-[3-(meth)acrylamidopropyloxy-2-hydroxypropyloxy-propyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acrylamido-isopropyloxy-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acrylamidobutyloxy-2-hydroxypropyloxy-propyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloylamido-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl polydimethylsiloxane, α-[3-[N-methyl-(meth)acryloylamido]-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl polydimethylsiloxane, N-methyl-N'-(propyl-tetra(dimethylsiloxy)dimethylbutylsilane) (meth)acrylamide, A method selected from the group consisting of N-(2,3-dihydroxypropane)-N'-(propyltetra(dimethylsiloxy)dimethyl-butylsilane) (meth)acrylamide, (meth)acryloylamido-propyltetra(dimethylsiloxy)-dimethylbutylsilane, and combinations thereof.
[0226] 32. A method in any one of embodiments 13 to 31, wherein the second monomer mixture comprises at least one polysiloxane vinyl crosslinking agent selected from the group consisting of α,ω-(meth)acryloxy-terminated polydimethylsiloxane; α,ω-(meth)acrylamido-terminated polydimethylsiloxane; α,ω-vinyl carbonate-terminated polydimethylsiloxane; α,ω-vinyl carbamate-terminated polydimethylsiloxane; bis-3-methacryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane; reaction product of glycidyl methacrylate and diamino-functionalized polydimethylsiloxane; reaction product of azlactone-containing vinyl monomer and dihydroxyl-functionalized polydimethylsiloxane; and combinations thereof.
[0227] 33. In any one of embodiments 13 to 31, the second monomer mixture comprises at least one polysiloxane vinyl crosslinking agent of the following formula H, and
[0228] [Chemical Formula H]
[0229]
[0230] In the above formula:
[0231] d1 is an integer from 30 to 500 and d2 is an integer from 1 to 75, provided that d2 / d1 is about 0.035 to about 0.15 (preferably about 0.040 to about 0.12, more preferably about 0.045 to about 0.10);
[0232] X h1 is O or NR hN is R hN Silver, hydrogen, or C1-C 10 -alkyl and;
[0233] R h0 It is hydrogen or methyl;
[0234] R h1 and R h2 are independently substituted or non-substituted C1-C 10 alkylene divalent radical or -Rh4 -OR h5 - is a divalent radical and R h4 and R h5 are independently substituted or non-substituted C1-C 10 It is an alkylene divalent radical;
[0235] R h3 is a monovalent radical of any one of the following chemical formulas Ha to He;
[0236] [Chemical Formula Ha]
[0237]
[0238] [Chemical Formula Hb]
[0239]
[0240] [Chemical formula Hc]
[0241]
[0242] [Chemical Formula Hd]
[0243]
[0244] [Chemical formula He]
[0245]
[0246] k1 is 0 or 1; m1 is an integer from 2 to 4; m2 is an integer from 1 to 5; m3 is an integer from 3 to 6; m4 is an integer from 2 to 5;
[0247] R h6 It is hydrogen or methyl;
[0248] R h7 It is a C2-C6 hydrocarbon radical having an (m2+1) valence;
[0249] R h8 It is a C2-C6 hydrocarbon radical having an (m4+1) valence;
[0250] R h9 is ethyl or hydroxymethyl;
[0251] R h10 is methyl or hydromethyl;
[0252] R h11 is hydroxyl or methoxy;
[0253] X h1 Silver -S- sulfur connector or -NR h12 - is the tertiary amino linker of and R h12 is a C1-C1 alkyl, hydroxyethyl, hydroxypropyl, or 2,3-dihydroxypropyl;
[0254] X h2 Is or It is a connector of and R h13 Silver, hydrogen, or C1-C 10 Alkyl, method
[0255] 34. A method in any one of embodiments 13 to 31, wherein the second monomer mixture comprises (i) at least one polysiloxane vinyl crosslinker comprising one single polydiorganosiloxane segment and two terminal ethylene-based unsaturated groups (which are selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, and vinyl carbamate groups); and / or (2) at least one chain-extended polysiloxane vinyl crosslinker having at least two polydiorganosiloxane segments and a covalent linker between each pair of polydiorganosiloxane segments and two terminal ethylene-based unsaturated groups (which are selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, and vinyl carbamate groups).
[0256] 35. In any one of embodiments 13 to 31, the second monomer mixture comprises α,ω-bis[3-(meth)acrylamidopropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxyethoxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxypropyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxy-isopropyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidoethoxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidoethoxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidopropyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidoisopropyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidobutyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidobutyloxy-2-hydroxypropyloxypropyl]-terminated Polydimethylsiloxane, α,ω-bis[3-(meth)acryloxypropylamino-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxybutylamino-2-hydroxypropyloxy-propyl]-terminated polydimethylsiloxane, α,ω-bis[(meth)acrylamidoethylamino-2-hydroxypropyloxy-propyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamido-propylamino-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamido-propylamino-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[(meth)acrylamide-butylamino-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[(meth)acryloxy-2-hydroxypropyloxy-ethoxypropyl]-terminated Polydimethylsiloxane,A method comprising (i) at least one polysiloxane vinyl crosslinking agent selected from the group consisting of α,ω-bis[(meth)acryloxy-2-hydroxypropyl-N-ethylaminopropyl]-terminated polydimethylsiloxane, α,ω-bis[(meth)acryloxy-2-hydroxypropyl-aminopropyl]-polydimethylsiloxane, α,ω-bis[(meth)acryloxy-2-hydroxypropyloxy-(polyethyleneoxy)propyl]-terminated polydimethylsiloxane, α,ω-bis[(meth)acryloxyethylamino-carbonyloxyethoxy-propyl]-terminated polydimethylsiloxane, α,ω-bis[(meth)acryloxyethylamino-carbonyloxy-(polyethyleneoxy)propyl]-terminated polydimethylsiloxane, and combinations thereof.
[0257] 36. In any one of embodiments 13 to 31, the second monomer mixture is It comprises at least one polysiloxane vinyl crosslinker having a polymer chain segment (i.e., a divalent radical), wherein SN is an integer of 3 or more and each R S1 and R S2 C1-C are independent of each other 10 Alkyl; Phenyl; C1-C4-alkyl-substituted phenyl; C1-C4-alkoxy-substituted phenyl; Phenyl-C1-C6-alkyl; C1-C 10 Fluoroalkyl; C1-C 10 Fluoroether; aryl; aryl C1-C 18 Alkyl; -alk-(OC2H4) γ1 -OR o (Here, alk is a C1-C6 alkylene diradal, and R o is H or C1-C4 alkyl and γ1 is an integer from 1 to 10); hydroxyl group (-OH), carboxyl group (-COOH), -NR N1 -'s amino linker, -CONR N1 -amide linker of, -CONR N1 R N1 amide of, -OCONH- urethane linker, and C1-C4 alkoxy group, or linear hydrophilic polymer chain (where, R N1 and RN1 ' are independently hydrogen or C1-C 15 C2-C having at least one functional group selected from the group consisting of alkyls 40 A method selected from a group of organic radicals.
[0258] 37. In any one of embodiments 13 to 31, the second monomer mixture comprises at least one polysiloxane vinyl crosslinking agent of the following formula 1 or 2, and
[0259] [Chemical Formula 1]
[0260]
[0261] [Chemical Formula 2]
[0262]
[0263] In the above formula:
[0264] R o is H or methyl;
[0265] υ1 is an integer from 30 to 500; υ2 and υ3 are independently integers from 5 to 100; ω2 and ω3 are independently integers from 1 to 15;
[0266] a1 and g1 are independently 0 or 1;
[0267] L1 is a C2-C8 alkylene divalent radical or , , , , , , or The divalent radical of;
[0268] L1' is a C2-C8 alkylene divalent radical having 0 or 1 hydroxyl group;
[0269] L1" is a C3-C8 alkylene divalent radical having 0 or 1 hydroxyl group;
[0270] L2 is , , , , or The divalent radical of;
[0271] L3 is The divalent radical of, and PE is or The divalent radical of;
[0272] L3' is a C3-C8 alkylene divalent radical;
[0273] R2 is C4-C 14 It is a divalent hydrocarbon radical;
[0274] R3 is a C2-C6 alkylene divalent radical;
[0275] X o , X1', and X o1 are independently O or NR1 and;
[0276] X1 is O, NR1, NHCOO, OCONH, CONR1, or NR1CO;
[0277] Z0 is directly bonded or C1-C 12 Method of an alkylene divalent radical.
[0278] 38. In any one of embodiments 13 to 37, the second monomer mixture comprises at least one silicon-containing vinyl monomer of the following formula M1 or M2, and
[0279] [Chemical Formula M1]
[0280]
[0281] [Chemical Formula M2]
[0282]
[0283] In the above formula: a M1 is 0 or 1 and; R M0 is H or methyl; X M0 is O or NR M1 Igo; L M1 C2-C8 alkylene divalent radical or , , , , , , or The divalent radical of; L M1 ' is a C2-C8 alkylene divalent radical having 0 or 1 hydroxyl group; L M1 is a C3-C8 alkylene divalent radical having 0 or 1 hydroxyl group; X M1 은 O, NR M1 , NHCOO, OCONH, CONR M1 , or NR M1 CO and; R M1 is H, or a C1-C4 alkyl having 0 or 2 hydroxyl groups; R t1 and R t2 are independently C1-C6 alkyls; X M1 A method in which ' is O or NR1; v1 is an integer from 1 to 30; v2 is an integer from 0 to 30; n1 is an integer from 3 to 40; and r1 is an integer from 2 or 3.
[0284] 39. In Embodiment 38, the at least one silicon-containing vinyl monomer is tris(trimethylsilyloxy)silylpropyl(meth)acrylate, [3-(meth)acryloxy-2-hydroxypropyloxy]propylbis(trimethylsiloxy)methylsilane, [3-(meth)acryloxy-2-hydroxypropyloxy]propylbis(trimethylsiloxy)butylsilane, 3-(meth)acryloxy-2-(2-hydroxyethoxy)propyloxy)propylbis(trimethylsiloxy)methylsilane, 3-(meth)acryloxy-2-hydroxypropyloxy)propyltris(trimethylsiloxy)silane, N-2-(meth)acryloxyethyl-O-(methyl-bis-trimethylsiloxy-3-propyl)silyl carbamate, 3-(trimethylsilyl)propylvinyl carbonate, A method comprising 3-(vinyloxycarbonylthio)propyltris(trimethylsiloxy)silane, 3-[tris(trimethylsiloxy)silyl]-propylvinyl carbamate, 3-[tris(trimethylsiloxy)silyl]propyl allyl carbamate, 3-[tris(trimethylsiloxy)silyl]-propyl vinyl carbonate, or a combination thereof.
[0285] 40. In any one of embodiments 13 to 37, the second monomer mixture comprises α-(meth)acryloxypropyl-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-(meth)acryloxy-2-hydroxypropyloxypropyl-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-(2-hydroxyl-methacryloxypropyloxypropyl)-ω-C1-C4-alkyl-decamethylpentasiloxane, α-[3-(meth)acryloxyethoxy-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloxy-propyloxy-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloxyisopropyloxy-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloxybutyloxy-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloxyethylamino-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloxypropylamino-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[3-(meth)acryloxy-butylamino-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated Polydimethylsiloxane, α-[(meth)acryloxy-(polyethyleneoxy)-2-hydroxypropyloxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[(meth)acryloxy-2-hydroxypropyloxy-ethoxypropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[(meth)acryloxy-2-hydroxypropyl-N-ethylaminopropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[(meth)acryloxy-2-hydroxypropyl-aminopropyl]-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-[(meth)acryloxy-2-hydroxypropyloxy-(polyethyleneoxy)propyl]-terminated ω-C1-C4-alkyl-terminated Polydimethylsiloxane,A method comprising at least one silicone-containing vinyl monomer selected from the group consisting of α-vinyl carbonate-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, α-vinyl carbamate-terminated ω-C1-C4-alkyl-terminated polydimethylsiloxane, or mixtures thereof.
[0286] 41. A method in any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b), and (c) in the second monomer mixture is at least about 60 weight% relative to the total weight of all polymerizable materials present in the second monomer mixture.
[0287] 42. A method in any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b), and (c) in the second monomer mixture is at least about 65% by weight relative to the total weight of all polymerizable materials present in the second monomer mixture.
[0288] 43. A method in any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b), and (c) in the second monomer mixture is at least about 70 weight% relative to the total weight of all polymerizable materials present in the second monomer mixture.
[0289] 44. A method in any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b), and (c) in the second monomer mixture is at least about 75% by weight relative to the total weight of all polymerizable materials present in the second monomer mixture.
[0290] 45. A method in any one of embodiments 1 to 44, wherein the at least one polymerizable material comprises at least one non-silicon vinyl crosslinking agent.
[0291] 46. In any one of Embodiments 1 to 44, the at least one polymerizable material is ethylene glycol di-(meth)acrylate, diethylene glycol di-(meth)acrylate, triethylene glycol di-(meth)acrylate, tetraethylene glycol di-(meth)acrylate, glycerol di-(meth)acrylate, 1,3-propanediol di-(meth)acrylate, 1,3-butanediol di-(meth)acrylate, 1,4-butanediol di-(meth)acrylate, glycerol 1,3-diglycerolate di-(meth)acrylate, ethylenebis[oxy(2-hydroxypropane-1,3-diyl)] di-(meth)acrylate, bis[2-(meth)acryloxyethyl] phosphate, trimethylolpropane di-(meth)acrylate, and 3,4-Bis[(meth)acryloyl]tetrahydrofuran, diacrylamide (i.e., N-(1-oxo-2-propenyl)-2-propenamide), dimethacrylamide (i.e., N-(1-oxo-2-methyl-2-propenyl)-2-methyl-2-propenamide), N,N-di(meth)acryloyl-N-methylamine, N,N-di(meth)acryloyl-N-ethylamine, N,N'-methylene bis(meth)acrylamide, N,N'-ethylene bis(meth)acrylamide, N,N'-dihydroxyethylene bis(meth)acrylamide, N,N'-propylene bis(meth)acrylamide, N,N'-2-hydroxypropylene bis(meth)acrylamide, N,N'-2,3-dihydroxybutylene bis(meth)acrylamide, Comprising at least one non-silicon vinyl crosslinking agent selected from the group consisting of 1,3-bis(meth)acrylamide-propane-2-yl dihydrogen phosphate (i.e., N,N'-2-phosphonyoxypropylene bis(meth)acrylamide), piperazine diacrylamide (or 1,4-bis(meth)acryloylpiperazine), tetraethylene glycol divinyl ether, triethylene glycol divinyl ether, diethylene glycol divinyl ether, ethylene glycol divinyl ether, trialyl isocyanurate, trialyl cyanurate, trimethylpropane trimethacrylate, pentaerythritol tetramethacrylate, bisphenol A dimethacrylate, and combinations thereof,method.,
[0292] 47. A method in any one of embodiments 1 to 44, wherein the at least one polymerizable material comprises at least one non-silicon vinyl crosslinking agent selected from the group consisting of tetra(ethylene glycol) di-(meth)acrylate, tri(ethylene glycol) di-(meth)acrylate, ethylene glycol di-(meth)acrylate, di(ethylene glycol) di-(meth)acrylate, tetraethylene glycol divinyl ether, triethylene glycol divinyl ether, diethylene glycol divinyl ether, ethylene glycol divinyl ether, trialyl isocyanurate, trialyl cyanurate, or a combination thereof.
[0293] 48. A method in any one of embodiments 1 to 47, wherein the at least one polymerizable material comprises at least one non-silicon hydrophobic vinyl monomer.
[0294] 49. In any one of Embodiments 1 to 47, the at least one polymerizable material is at least one C1-C8 alkyl (meth)acrylate, at least one C5-C 16 A method comprising cycloalkyl (meth)acrylate, at least one aryl methacrylate, (meth)acrylonitrile, at least one fluorine-containing acrylic monomer, at least one vinyl alkanoate, at least one vinyloxyalkane, at least one substituted or unsubstituted styrene, vinyl toluene, vinyl chloride, vinylidene chloride, 1-butene, or a combination thereof.
[0295] 50. In Embodiment 49, the at least one vinyl alkanoate is selected from the group consisting of vinyl acetate, vinyl propionate, vinyl butyrate, vinyl valerate, and combinations thereof, the at least one vinyloxyalkane is selected from the group consisting of vinyl ethyl ether, propyl vinyl ether, n-butyl vinyl ether, isobutyl vinyl ether, cyclohexyl vinyl ether, t-butyl vinyl ether, and combinations thereof, and the at least one fluorine-containing acrylic monomer is 2,2,2-trifluoroethyl (meth)acrylate, tetrafluoropropyl (meth)acrylate, hexafluoro-iso-propyl (meth)acrylate, hexafluorobutyl (meth)acrylate, heptafluorobutyl (meth)acrylate, octafluoropentyl (meth)acrylate, heptadecafluorodecyl (meth)acrylate, pentafluorophenyl A method selected from the group consisting of (meth)acrylates, perfluorohexylethyl-thio-carbonyl-aminoethyl-methacrylates, and combinations thereof.
[0296] 51. A method in any one of embodiments 1 to 47, wherein the at least one polymerizable material comprises methyl methacrylate, ethyl methacrylate, isopropyl methacrylate, sec-butyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, phenyl methacrylate, 4-tert-butylstyrene, 2-methylstyrene, styrene, 4-ethoxystyrene, 2,4-dimethylstyrene, 2,5-dimethylstyrene, 3,5-dimethylstyrene, or a combination thereof.
[0297] 52. A method in any one of embodiments 1 to 47, wherein the at least one polymerizable material comprises methyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, or a combination thereof.
[0298] 53. A method in any one of embodiments 1 to 47, wherein the at least one polymerizable material comprises methyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, or a combination thereof.
[0299] 54. A method in any one of embodiments 1 to 53, wherein the at least one polymerizable material comprises at least one UV-absorbing vinyl monomer.
[0300] 55. A method in any one of embodiments 1 to 53, wherein at least one polymerizable material comprises 2-[2'-hydroxy-5'-(2-methacryloxyethyl)phenyl)]-2H-benzotriazole (Norbloc).
[0301] 56. A method in any one of embodiments 1 to 55, wherein the second polymerizable fluid composition comprises at least one photochromic compound.
[0302] 57. In Embodiment 56, the at least one photochromic compound is naphtopyran, indeno-fused naphtopyran (i.e., indeno-naphtopyran), heterocyclic ring-fused naphtopyran, benzopyran, phenantropyran, quinopyran, quinolinopyran, fluoroantenopyran, anthracene-fused pyran, tetracene-fused pyran, spiro(benzindolin)naphtopyran, spiro(indolin)naphtopyran, spiro(indolin)benzopyran, spiro(indolin)quinopyran, spiro(indolin)pyran, naphthoxazine, spirobenzopyran, spirobenzothiopyran, naphthacenedione, benzoxazine, spirooxazine, naphthoxazine, spiro(benzindolin)naphthoxazine, spiro(indolin)naphthoxazine, Spiro(indoline)pyrido-benzoate, Spiro(indoline)-benzoate, Spiro(benzindolin)benzoate, Spiro(benzindolin)pyridobenzoate, Spiro(indoline)fluolanthenox, Spiro(indoline)quinox, Spiropiperidine-naphtopyran, Pyro(indoline)pyronobenzoate, Benzospiropyran, Naphtospiropyran, Spirobenzoate-pyrrolopyridine, Spironaphtok-pyrrolopyridine, Spiro-oxazepine-benzoate, Spiro(indoline)benzophyrolox, Spiro(indoline)quinazolino-oxoate, Spiro(indoline)anthracenobenzoate, Benzofurobenzopyran, A method comprising benzothienobenzopyran, naphthofurobenzopyran, benzopyrano-fused naphthopyran, spiro(isoindoline)-naphtoxazine, spiro(isoindoline)benzoxazine, or a mixture thereof.
[0303] 58. In Embodiment 56, the method wherein at least one photochromic compound is polymerizable (i.e., containing an ethylene-based unsaturated group).
[0304] 59. In Embodiment 58, the at least one photochromic compound is a coupling reaction product of a reactive (meth)acrylamido or (meth)acryloxy monomer having a first reactive functional group, and the reactive photochromic compound has a second reactive functional group in the absence or presence of a coupling agent during the coupling reaction, and the first reactive functional group is -COCl, -COBr, -COOH, -NHR N2 , -NCO, -OH, -CHO, , , or Selected from the group consisting of, and the second reactive functional group is -COOH, -NHR N2 , , , , -NCO, -OH, -SH, -CHO, , , or Selected from the group consisting of, where R0 is hydrogen or methyl and R N2 is hydrogen, linear or branched C1-C 15 A method in which alkyl, cyclohexyl, cyclopentyl, substituted or unsubstituted phenyl, or substituted or unsubstituted phenyl-C1-C6 alkyl.
[0305] 60. In Embodiment 59, the reactive (meth)acrylamido or (meth)acryloxy monomer is a (meth)acryloyl halide (CH2=CH─COX or CH2=CCH3─COX, X=Cl or Br), N-hydroxysuccinimide ester of (meth)acrylic acid, glycidyl (meth)acrylate, isocyanato-C2-C6 alkyl (meth)acrylate, amino-C2-C6 alkyl (meth)acrylamide, C1-C6 alkylamino-C2-C6 alkyl (meth)acrylamide, (meth)acrylic acid, C2-C4 alkylacrylic acid (e.g., ethylacrylic acid, propylacrylic acid, butylacrylic acid), N-2-acrylamidoglycolic acid, 3-(acryloyloxy)propanoic acid, C2-C6 hydroxyalkyl (Met)acrylate, C2-C6 hydroxyalkyl (meth)acrylamide, azlactone-containing vinyl monomer (e.g., 2-vinyl-4,4-dimethyl-1,3-oxazolin-5-one, 2-isopropenyl-4,4-dimethyl-1,3-oxazolin-5-one, 2-vinyl-4-methyl-4-ethyl-1,3-oxazolin-5-one, 2-isopropenyl-4-methyl-4-butyl-1,3-oxazolin-5-one, 2-vinyl-4,4-dibutyl-1,3-oxazolin-5-one, 2-isopropenyl-4-methyl-4-dodecyl-1,3-oxazolin-5-one, 2-isopropenyl-4,4-diphenyl-1,3-oxazolin-5-one, As 2-isopropen-4,4-pentamethylene-1,3-oxazolin-5-one, 2-isopropen-4,4-tetramethylene-1,3-oxazolin-5-one, 2-vinyl-4,4-diethyl-1,3-oxazolin-5-one, 2-vinyl-4-methyl-4-nonyl-1,3-oxazolin-5-one, 2-isopropen-4-methyl-4-phenyl-1,3-oxazolin-5-one, 2-isopropen-4-methyl-4-benzyl-1,3-oxazolin-5-one, 2-vinyl-4,4-pentamethylene-1,3-oxazolin-5-one, and 2-vinyl-4,4-dimethyl-1,3-oxazolin-6-one, the preferred azlactone-containing vinyl monomer is 2-vinyl-4,4-dimethyl-1,3-oxazolin-5-one (VDMO) and 2-isopropenyl-4,4-dimethyl-1,3-oxazolin-5-one (IPDMO), aziridinyl C1-C 12A method selected from the group consisting of alkyl (meth)acrylates (e.g., 2-(1-aziridinyl)ethyl (meth)acrylate, 3-(1-aziridinyl)propyl (meth)acrylate, 4-(1-aziridinyl)butyl (meth)acrylate, 6-(1-aziridinyl)hexyl (meth)acrylate, or 8-(1-aziridinyl)octyl (meth)acrylate), acrolein, methacrolein, crotonaldehyde, and combinations thereof.
[0306] 61. In Embodiment 59 or Embodiment 60, the reactive photochromic compound is 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-propyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxy-13-propyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-(2-hydroxycarbonylethyl)carboxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxymethyl-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-(2-hydroxycarbonylethyl)carboxymethyl-13-methyl-3H,13H-indeno[2',3':3,4]-naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran;3,3-Bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno-[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-11-phenyl-13-hydroxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-11-phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,7,10,11-tetramethyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno[2',3':3,4]-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11-(4-(4,5-diphenyl-1H-imidazole-2-yl)phenyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6-methoxy-7-(3-hydroxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3,3-di(4-methoxyphenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)-carboxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-hydroxyethoxy)-ethoxy)-indeno[2,1-f]naphtho[1,2-b]pyran;3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-diphenyl-13-hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11-dimethyl-13-butyl-13-hydroxy-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13,13-diethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13,13-dipropyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13-carbomethoxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-diphenyl-6,7-dimethoxy-13-methyl-13-methyl-13-hydroxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-diphenyl-6,7,10,11-tetramethoxy-13-ethyl-13-methyl-13-hydroxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 6,7-Dimethoxy-2,2-Diphenyl-13-hydroxy-13-butyl-2H,13H-Indeno[1',2':4,3]Naphtho[1,2-b]pyran; 6,7-Dimethoxy-2,2-Diphenyl-13-hydroxy-13-methyl-2H,13H-Indeno[1',2':4,3]Naphtho[1,2-b]pyran; 6,7-Dimethoxy-2,2-Diphenyl-13-hydroxy-2H,13H-Indeno[1',2':4,3]Naphtho[1,2-b]pyran; 3-(4-allyloxyphenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran;3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(piperazine-1-yl)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(4-hydroxybenzamido)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-vinyl-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(carboxylic acid)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3-(4-fluorophenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-hydroxyethoxyphenyl)-3-(4-methoxyphenyl)-11-(4-(N,N-dimethylamino)phenyl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(2,4-dimethoxyphenyl)-phenyl-6,11-dimethoxy-13-methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran;3-(4-methoxyphenyl)-3-(3-methyl-4-methoxyphenyl)-13-hydroxy-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-deno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7-dimethoxy-13-hydroxy-13-methyl-3H,13H-deno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-13-oxo-3H,13H-deno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6-methoxy-7-morpholino-13-methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6,11-dimethoxy-13-methyl-13-methyl-13-hydroxyethoxy-ethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-oxo-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran;3-phenyl-3-(4-hydroxyethoxyphenyl)-6-methoxy-7-morpholino-13,13-dimethyl-3H,13H-indeno-[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxyethoxy-phenyl)-6-methoxy-7-morpholino-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxyethoxy)phenyl)-6-methoxy-7-piperidino-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-(2-hydroxycarbonylethyl)-carboxyethoxy)phenyl)-6-methoxy-7-piperidino-13,13-dimethyl-3H,13H-indene[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-hydroxyphenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-hydroxyethoxy)phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxyethoxy)phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxy-phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-(2-hydroxyethyl)piperazine-1-yl)phenyl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-(2-(2-hydroxycarbonylethyl)-carboxyethyl)piperazine-1-yl)phenyl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-piperazinyl-13,13-dimethyl-3H,13H-indene[2',3':3,4]naphtho[1,2-b]pyran;3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(3-hydroxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)carboxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4-hydroxypifenidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)-carboxypifenidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-methoxyphenyl-piperazine-1-yl)phenyl)-13,13-dimethyl-6-methoxy-7-hydroxy-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-methoxyphenyl-piperazine-1-yl)phenyl)-13,13-dimethyl-6-methoxy-7-(2-hydroxy-2-methyl-3-butin-4-yl)-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-hydroxymethylene-piperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonyl-ethyl)carboxymethylene-piperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3.4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)carboxymethylene-piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran;3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)-carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-piperazinyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6,11-dimethyl-13-hydroxy-13-(1-oxo-methoxyprop-2-yl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)-phenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)phenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6,11-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6-methoxy-7-piperidinyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(3-methylpiperazine-1-yl)phenyl)-6-methoxy-7-(decahydroisoquinoline-2-yl)-11-tert-butyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-16-(ethoxycanobyl)methyl-16-hydroxy-3,16-dihydrobenzofuro-[2',3':7,8]indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-16-(ethoxycanobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro [2”,3”:6',7']indeno-[3',2':4,3]naphtho[1,2-b]pyran;3-phenyl-3-(4-morpholinophenyl)-16-(ethoxycanobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro[2”,3”:6',7']deno[3',2':4,3]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-(ethoxycarbonyl)methyl-16-hydroxy-3,16-dihydro-benzofuro[2',3':7,8]deno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16-ethyl-16H-benzofuro[2',3':7,8] indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16H-benzofuro[2”,3”:6,7]indeno[3',2':4,3]naphtho-[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16-ethyl-16H-benzofuro[2”,3”:6,7]-indeno[3',2':4,3]naphtho[1,2-b]pyran; A method comprising 3-(4-methoxyphenyl)-3-(2,3-dihydrobenzofuro-5-yl)-13-hydroxy-13-methyl-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(2,3-dihydrobenzofuro-5-yl)-6,11-difluoro-13-hydroxy-13-(1-oxo-methoxyprop-2-yl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran, or a mixture thereof.;
[0307] 62. In Embodiment 59 or Embodiment 60, the reactive photochromic compound is 2,2-di(4-fluorophenyl)-5-hydroxycarbonyl-6-phenyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methylphenyl)-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-hydroxy-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-vinyl-2H-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-hydroxycarbonyl-2H-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(2-hydroxyethoxy)ethoxy-[2H]-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxycarbonyl-6-phenyl-9-(2-hydroxyethoxy)-[2H]-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxy-carbonyl-6-(4-(2-hydroxyethoxy)phenyl)-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-hydroxyethoxylcarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-hydroxyethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-(2-hydroxyethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-phenyl-2H-naphtho[1,2-b]pyran;2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(3-aminophenyl)-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-2,5,7-trihydro-7-methylidine-5-oxo-furo-[3',4':3,4]naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-13-hydroxy-13-methyl-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-9-methoxycarbonyl-8-(2-hydroxyethoxy)ethoxy-[3H]-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-8,9-dimethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carbomethoxy-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-methylol-6-(3-dimethylaminopropyl)-methylamino-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-2,5,7-trihydro-7-methylidene-5-oxofuro-[3',4':3,4]naphtho[1,2-b]pyran; 2,2-spiroadamantylene-5-phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl)-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-spiro-admamtylene-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran, 3,3-diphenyl-8-hydroxy-9-carbopropoxy-3H-naphtho[2,1-b]pyran; 2,2,5-triphenyl-6-carboethoxy-2H-naphtho[1,2-b]pyran;2,2,6-triphenyl-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)-ethoxy)ethoxy)carbonyl-[2H]-naphtho[1,2-b]pyran; 2,2,6-triphenyl-5-(2-(2-(2-oxiran-2-ylmethoxy)ethoxy)ethoxy)-ethoxycarbonyl)-[2H]-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxy-phenyl)-2-tert-butyl-5-methoxy-carbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)-ethoxyphenyl)-2-phenyl-5-methoxycarbonyl-6-methyl-9-methoxy-[2H]-naphtho[1,2-b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-2-phenyl-5-methoxycarbonyl-6-(2-(2-methylprop-2-enoxyloxy)ethoxy)-[2H]-naphtho[1,2-b]pyran; 3-(4-(2-(2-hydroxyethoxy)-ethoxy)ethoxyphenyl)-3-phenyl-9-methoxycarbonyl-8-methoxy-[3H]-naphtho[1,2-b]pyran; 2-(4-morpholinophenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(9-ethylcarbazole-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(9-phenylcarbazole-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-dimethylaminophenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 3-(2-fluorophenyl)-3-(4-methoxyphenyl-8-hydroxy-9-carbopropoxy-3H-naphtho[2,1-b]pyran; 3-(2-fluorophenyl)-3-(4-methoxyphenyl-8-hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran; 3-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl-8-hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran;3-(2,4,6-trifluorophenyl)-3-(2,4,6-trimethoxy-1-naphthyl)-8-acetyl-9-carbonylloyl-3H-naphtho[2,1-b]pyran; 3-(4-methoxyphenyl)-3-(2-methyl-2,3-dihydrobenzofuro-5-yl)-6-methoxy-12-hydroxymethyl-11-phenyl-3H-phenantro[1,2-b]pyran; 5,5-bis(4-methoxyphenyl)-8-methylol-5H-fluoranteno[3,2-b]pyran; or a mixture thereof, a method.;
[0308] 63. In Embodiment 59 or Embodiment 60, the reactive photochromic compound is 1-hydroxyethyl-3,3-dimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-hydroxypropyl-3,3-dimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-aminoethyl-3,3-dimethyl-5-chlorospiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-hydroxyethyl-3,3-dimethyl-8'-methoxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-(p-vinylphenyl)-3,3-dimethyl-5,6-dichlorospiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9'-hydroxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5'-hydroxymethylspiro-[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9'-aminospiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5-chloro-8'-hydroxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-9'-vinylbenzoyoxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-5'-hydroxymethylpiperidinospironaphthooxazine; 1,3,3-trimethyl-9'-hydroxyspiro[indolin-2,3'-[3H]-pyrido-[2,1-b][1,4]benzoxazine]; 5-hydroxy-6'-cyano-1,3,3-trimethyl-spiro-[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-hydroxy-6'-phenylsulfonyl-1,3,3-trimethyl-spiro-[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5'formyl-1,3,3-trimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-dihydro-6'-piperazino-1,3,3-trimethylspiro[2H indole-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine;1,3-Dihydro-6'-(4-hydroxyethyl)piperazino-1,3,3-trimethylspiro[2H indole-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-Dihydro-9'-hydroxy-1,3,3-trimethylspiro[2H indole-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3,3,4,5-pentamethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]naphtho[2,1-b][1,4]oxazine; 1,3,3,5,6-pentamethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]napt[2,1-b][1,4]oxazine; 1-propyl-3,3,4,5-tetramethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]napt[2,1-b][1,4]oxazine; 1-propyl-3,3,5,6-tetramethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]napt[2,1-b][1,4]oxazine; 1-Methoxyethyl-3,3-Dimethyl-9'-Allyloxycarbonyl-8'-Chloroactoxy-spiro[Indolin-2,3'-[3H]Napt[2,1-b][1,4]Oxazine; 1-Allyl-3,3-Spirocyclohexyl-9'-Benzyloxycarbonyl-8'-Chloroactoxy-spiro[Indolin-2,3'-[3H]Napt-[2,1-b][1,4]Oxazine; 5-Amino-1,3,3-Trimethyl-spiro[Indolin-2,3'-[3H]-Pyrido[3,4-f][1,4]-Benzoxazine; 6-Hydroxy-1',3',3',4',5'-Pentamethylspiro[2H-1,4-Benzoxazine-2,2'-Indolin]; 6-hydroxy-1',3',3',5',6'-pentamethylspiro[2H-1,4-benzoxazine-2,2'-indolin]; 5,7-dimethoxy-1'-hydroxy-carbonylethyl-3',3'-dimethylspiro[2H-1,4-benzoxazine-2,2'-indolin]; 7-methoxy-1'-hydroxy-ethyl-3',3'-dimethylspiro[2H-1,4-benzoxazine-2,2'-indolin]; 9'-hydroxy-1-methyl-spiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 5-chloro-9'-hydroxy-1-methylspiro-[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine];8'-hydroxy-1-methylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 8'-hydroxy-5-methoxy-1-methylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 8'-hydroxy-1,4,5-trimethylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9'-hydroxy-1-isopropylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9'-hydroxy-1-hexadecyl-spiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9'-hydroxy-1-octadecylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 1,1”-(1,5-pentanediyl)bis[3,3-dimethyl]-9'-hydroxy-spiro[indolin-2,3'-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-[1,4-phenylenebis(methylene)]bis[3,3-dimethyl]-5'-hydroxymethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-(1,4-butanediyl)bis[5,6-dichloro-3,3-dimethyl]-8'-hydroxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9'-hydroxypiperidinospyronafthoxazine; 3-carboxyethyl-1,1-dimethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-carboxyethyl-3,3-dimethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,1-dimethyl-3-hydroxyethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 3,3-dimethyl-1-hydroxyethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 3-carboxyethyl-1,1-dimethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine];1-Carboxyethyl-3,3-dimethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine]; 1,1-dimethyl-3-hydroxyethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine]; 3,3-dimethyl-1-hydroxyethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine]; A method comprising: 5-amino-5'-(2-benzthiazolyl)-1,3,3-trimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-amino-5'-(5'-(2-hydroxyphenyl)-2-oxadiazolyl)-1-isopropyl-3,3-dimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-amino-5'-(5'-phenyl-2-oxadiazolyl)-1,3,3-trimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; or a mixture thereof.;
[0309] 64. In Embodiment 59 or Embodiment 60, the reactive photochromic compound is 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; or a method that is a mixture of these.
[0310] 65. A method in any one of embodiments 1 to 64, wherein the at least one photochemical functional compound comprises at least one polymerizable UV / HEVL absorbing compound.
[0311] 66. A method in any one of embodiments 1 to 64, wherein the at least one photochemical functional compound comprises at least one polymerizable fluorescent compound.
[0312] 67. A method in any one of embodiments 1 to 66, wherein the at least one first free radical initiator comprises a benzoylphosphine initiator and / or an acylgermanium photoinitiator.
[0313] 68. In Embodiment 67, the at least one first free radical initiator is , , or A method comprising an acyl-germanium photoinitiator.
[0314] 69. Method according to Embodiment 67 or Embodiment 68, wherein the UV or visible light (UV / visible) is visible light in the range of 420 nm to 500 nm.
[0315] 70. A method in any one of embodiments 1 to 69, wherein the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable composition and the second polymerizable fluid composition is about 4.0% or less.
[0316] 71. A method in any one of embodiments 1 to 69, wherein the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable composition and the second polymerizable fluid composition is about 3.0% or less.
[0317] 72. A method in any one of embodiments 1 to 69, wherein the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable composition and the second polymerizable fluid composition is about 2.5%.
[0318] 73. A method in any one of embodiments 1 to 72, wherein the original layer of the second polymerizable fluid composition is irradiated for a time of about 5% to about 65% of the second curing time.
[0319] 74. A method in any one of embodiments 1 to 72, wherein the original layer of the second polymerizable fluid composition is irradiated for a time of about 5% to about 65% of the second curing time.
[0320] 75. A method in any one of embodiments 1 to 72, wherein the original layer of the second polymerizable fluid composition is irradiated for a time of about 5% to about 40% of the second curing time.
[0321] 76. A hydrogel contact lens obtained according to any one of the methods of Embodiments 1 to 75.
[0322] The present disclosure will enable those skilled in the art to practice the invention. Various modifications, variations, and combinations of the various embodiments described herein may be made. To enable the reader to better understand specific embodiments and their benefits, it is suggested to refer to the following examples. The present specification and examples are intended to be regarded as exemplary.
[0323] Example 1
[0324] Oxygen permeability measurement
[0325] Unless otherwise specified, oxygen permeability (Dk / t) of the lens and lens material, intrinsic (or edge-corrected) oxygen permeability (Dk i or Dk c ) is measured according to the procedure described in ISO 18369-4.
[0326] Equilibrium water content
[0327] The equilibrium water content (EWC) of a contact lens is determined as follows.
[0328] Determine the amount of water (expressed as weight percent) present in a fully equilibrated, hydrated hydrogel contact lens in a saline solution at room temperature. Quickly stack the lenses, blot them with a cloth, and then transfer the lens stack to an aluminum pan on an analytical balance. The number of lenses per sample pan is typically five. Record the hydrated weight of the pan + lens. Cover the pan with aluminum foil. Place the pan in a laboratory oven at 100±2°C and dry it for 16 to 18 hours. Remove the pan + lens from the oven and cool it in a dryer for at least 30 minutes. Remove a single pan from the dryer and discard the aluminum foil. Weigh the pan + dried lens sample on an analytical balance. Repeat for all pans. The wet and dry weights of the lens sample can be calculated by subtracting the weight of the empty weighing pan.
[0329] Elastic modulus
[0330] The elastic modulus of a contact lens is measured using the MTS insight instrument. The contact lens is first cut into a 3.12 mm wide strip using a Precision Concept 2 stage cutter. Five thickness values are measured within a 6.5 mm gauge length. The strip is mounted on the instrument grip and immersed in PBS (phosphate-buffered saline) at a controlled temperature of 21 ± 2°C. Typically, a 5 N load cell is used for the test. A constant force and velocity are applied to the sample until the sample fractures. Force and displacement data are collected by TestWorks software. The elastic modulus value, which is the slope or tangent of the stress-strain curve at an elongation close to zero in the elastic deformation region, is calculated using TestWorks software.
[0331] transmittance
[0332] Manually place the contact lens into a specially designed sample holder, such as one that maintains the lens's shape as it would when placed in the eye. Then, using this holder as a reference, immerse the lens in a 1 cm path-length quartz cell containing phosphate-buffered saline (PBS, pH approx. 7.0 to 7.4). A UV / visible spectrophotometer, such as a Varian Cary 3E UV-visible spectrophotometer equipped with a LabSphere DRA-CA-302 beam splitter, may be used for this measurement. Percent transmittance spectra are collected in the wavelength range of 250 to 800 nm, and %T values are collected at 0.5 nm intervals. Transfer this data to an Excel spreadsheet and use it to verify that the lens meets Class 1 UV absorbance standards. Calculate the transmittance using the following formula:
[0333] UVA %T = Average transmittance between 315 nm and 380 nm % x 100
[0334] UVB %T = Average transmittance between 280 nm and 315 nm % x 100
[0335] Violet %T = Average transmittance % between 380 nm and 440 nm x 100.
[0336] Optical Rheology: Photorheology experiments measure elasticity (G') and viscosity coefficient (G'') as a function of time during curing. The experiment is performed using an appropriate light source, a cutoff filter for selecting the wavelength of interest at will, and a rheometer. For example, the light source has a spectral center at approximately 452 nm and a pressure of approximately 54 mW / cm² 2 It may be an LED delivering visible light with a total irradiance (OPSYTEC DR. GROEBEL). Alternatively, the light source may be UV light (Hamamatsu, 330 nm cutoff filter, total irradiance 16 mW / cm²). 2 ) It may be. The sample (i.e., the polymerizable composition) is chemoradiated (i.e., at a spectral center of about 452 nm and about 54 mW / cm²2 It is placed between a quartz plate through which visible light (with a total irradiance) can pass and a rheometer. The curing time of the polymerizable composition is measured when the elastic modulus (G') reaches a stable state.
[0337] chemical substances
[0338] PrOH represents 1-propanol; DMA represents N,N-dimethylacrylamide; G-PDMS-D2 represents the hydrophilic polysiloxane vinyl crosslinker of formula (G) (Shin-Etsu); RhoMA represents the methacryloxyethyl thiocarbamoyl rhodamine B of formula R (fluorescent compound) (Polysciences); DC 1173 represents the Darocur 1173® photoinitiator; Ge-PI represents bis(4-methoxybenzoyl)diethylgermanium (acylgermanium photoinitiator); and SP-MA represents the (2-(3',3'-dimethyl-6-nitrospiro[cromen-2,2'-indolin]-1'-yl)ethyl methacrylate) of formula (S) (spriopyran photochromic dye of BLD Pharma).
[0339]
[0340] Example 2
[0341] Polymerizable composition
[0342] Two polymerizable compositions for forming a silicone hydrogel material are prepared by blending all essential components to have the compositions shown in Table 1.
[0343]
[0344] Research on photorheology
[0345] Photorheology data is UV light (Hamamatsu, 330 nm cutoff filter, total irradiance 16 mW / cm² 2 Formulations 2A and 2B are obtained by curing using ). The result in Fig. 2 indicates that G' is 120 kPa and the curing time is 20s.
[0346] Fabrication of SiHy contact lenses with a central fluorescent zone
[0347] Approximately 10 mg of Formulation 2B was injected into the center of the female (FC) mold half (made of polypropylene) of a plastic mold (Power: -3.0) to form a circular layer, and UV light (Hamamatsu, using a 330 nm cutoff filter, total irradiance 16 mW / cm²) was applied for 3 seconds. 2 It was partially cured using ). It was found that this part (the circular layer) could not flow freely in the open FC mold half. Approximately 30 mg of Formulation 2A was added to immerse the partially cured functional part (i.e., the circular layer), and then the mold was closed into the water (BC) mold half to form a molded assembly comprising Formulation 2A and the partially cured circular layer immersed therein. The molded assembly was further photocured using the same UV light for 40 seconds.
[0348] After curing, manually open the molded assembly and carefully remove the SiHy lens using tweezers with rubber tips. Then, hydrate the hydrogel lens in deionized water.
[0349] SiHy contact lenses having fluorescent central zones of different sizes were prepared according to the procedure described above, except that the amounts of formulations 2A and 2B were changed as follows: a) 3 mg formulation 2B and 37 mg formulation 2A; b) 6 mg formulation 2B and 34 mg formulation 2A; c) 9 mg formulation 2B and 31 mg formulation 2A; d) 12 mg formulation 2B and 28 mg formulation 2A.
[0350] Example 3
[0351] Polymerizable composition
[0352] Two polymerizable compositions for forming a silicone hydrogel material are prepared by blending all essential components to have the compositions shown in Table 2.
[0353]
[0354] Research on photorheology
[0355] The photorheological data is 54 mW / cm² 2 The two formulations prepared above were obtained by curing them using 452 nm LED light (OPSYTEC DR. GROEBEL) at the total irradiation intensity. The results are shown in Fig. 3. Replacing Darocur 1173 with Ge-PI in Formulation 3A (compared to Formulation 2A) had no effect on G' (G'=120 kPa for Formulation 2A compared to G'=120 kPa for Formulation 3A), but the curing time increased slightly (20 seconds for Formulation 2A compared to 24 seconds for Formulation 3A). Adding a photochromic dye slowed down the curing time (30 seconds for Formulation 3B) and showed no significant change in G' (G'=119 kPa for Formulation 3B). Therefore, equivalent lens characteristics for these SiHy lenses are expected under the LED curing system.
[0356] Fabrication of SiHy lenses with a central photochromic zone
[0357] Approximately 10 mg of Formulation 3B was injected into the center of the female (FC) mold half (made of polypropylene) of a plastic mold (Power: -3.0) to form a circular layer, and LED light (OPSYTEC DR. GROEBEL, total irradiance 54 mW / cm²) was applied for 2 seconds. 2 It was partially cured using ). It was observed that the functional portion (circular layer) could not flow freely in the open half of the FC mold. Approximately 30 mg of Formulation 3A was added to immerse the partially cured functional portion, and then the mold was closed to form a molded assembly comprising Formulation 3A and the partially cured circular layer immersed therein. The molded assembly was further photocured using the same LED light for 60 seconds.
[0358] After curing, manually open the molded assembly and carefully remove the SiHy lens using tweezers with rubber tips. Then, hydrate the SiHy lens in PBS.
[0359] Activate the lens with a central photochromic zone using a black light lamp for 2 minutes (peak at 365 nm, total irradiance 5 mW / cm²). 2 As ultraviolet light was removed, the SiHy lens gradually returned to the "off" state. Figure 4 shows the UV spectra (using a Lambda 850 spectrometer) of the central photochromic region ("on" state 10 and "off" state 11) and the peripheral region (outside the central photochromic region) ("on" state 20 and "on" state 21) before and after activation.
[0360] All publications and patents cited above in this application are incorporated herein by reference in their entirety.
Claims
Claim 1 A method for manufacturing a hydrogel contact lens, comprising the step of obtaining a first polymerizable fluid composition and a second polymerizable fluid composition, wherein the first polymerizable fluid composition comprises at least one photoinitiator and at least one polymerizable material and is free of any photochemical functional compounds, and the second polymerizable fluid composition comprises the at least one photoinitiator and the at least one polymerizable material and additionally at least one photochemical functional compound, and the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable fluid composition and the second polymerizable fluid composition is 5.0% or less, and the at least one photochemical functional compound is at least one photochromic compound, at least one UV / HEVL absorbing compound, at least one fluorescent compound, at least one color-filtering material for colorblind correction, at least one diffracting material, at least one high refractive index material, or a combination thereof, and the first polymerizable fluid composition has a first curing time and the second polymerizable fluid composition has a second curing time, and the first and second curing times are of a specific intensity Steps measured in photorheological studies using UV / visible light; (2) obtaining a lens mold comprising a female mold half having a first molding surface defining the front surface of a contact lens to be molded and a male mold half having a second molding surface defining the rear surface of a contact lens to be molded, wherein the female and male mold half accommodate each other when the mold is closed to form a mold cavity between the first and second molding surfaces; (3) applying a predetermined amount of a second polymerizable fluid composition onto the central area of the first molding part of the female mold half to form a circular layer of the second polymerizable fluid composition, wherein the diameter of the circular layer is 13.Step 00 mm or less; (4) irradiating a circular layer of the second polymerizable fluid composition with UV / visible light of a specific intensity for 5% to 75% of the second curing time to partially crosslink the circular layer of the second polymerizable fluid composition; (5) dispensing a predetermined amount of the first polymerizable fluid composition onto the partially crosslinked circular layer on the central region of the first molding surface; (6) closing the female mold half with the male mold half to form a molded assembly comprising the partially crosslinked circular layer immersed in the first polymerizable fluid composition within the mold cavity; (7) irradiating the molded assembly with UV / visible light of a specific intensity for at least 120% of the first curing time to form a raw hydrogel contact lens having a central region, wherein the central region is concentric with the central axis of the raw hydrogel contact lens and has a diameter of 13 mm or less, and at least one photochemical provided by the at least one photochemical functional compound A method comprising: (8) separating a molded assembly into a male mold half and a female mold half with a raw hydrogel contact lens attached to a lens-attached mold half, which is one of the male and female mold halfs; (9) removing the raw hydrogel contact lens from the lens-attached mold half; and (10) applying the raw hydrogel contact lens to a post-molding process comprising a hydration process and one or more other processes selected from the group consisting of extraction, surface treatment, packaging, sterilization, and combinations thereof. Claim 2 The method according to claim 1, wherein the first and second polymerizable fluid compositions can form a non-silicon hydrogel, and the at least one polymerizable material is a first monomer mixture comprising (a) at least one first hydrophilic vinyl monomer selected from the group consisting of at least one hydroxyl-containing vinyl monomer, N,N-dimethylarylamide, N-vinylpyrrolidone, at least one methylene-containing pyrrolidone monomer, and combinations thereof, and (b) at least one component selected from the group consisting of at least one non-silicon vinyl crosslinking agent, a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof. Claim 3 A method according to paragraph 2, wherein the at least one polymerizable material comprises at least 50 weight percent of at least one hydroxyl-containing vinyl monomer relative to the total weight of all polymerizable materials present in the first polymerizable fluid composition. Claim 4 A method according to claim 1, wherein the first and second polymerizable fluid compositions can form a non-silicon hydrogel, and the at least one polymerizable material is a reactive mixture comprising (a) one or more water-soluble non-silicon prepolymers and optionally (b) at least one component selected from the group consisting of a hydrophilic vinyl monomer, a non-silicon vinyl crosslinking agent, a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof. Claim 5 In claim 1, the first and second polymerizable fluid compositions can form a silicone hydrogel, and the at least one polymerizable material is a second monomer mixture comprising at least one component selected from the group consisting of (a) at least one silicone-containing vinyl monomer, (b) at least one polysiloxane vinyl crosslinker, at least one non-silicon vinyl crosslinker, or both, (c) at least one second hydrophilic vinyl monomer, and optionally (d) a non-silicon hydrophobic vinyl monomer, a UV-absorbing vinyl monomer, and combinations thereof, wherein the at least one second hydrophilic vinyl monomer is at least one hydrophilic (meth)acrylamido monomer having 3 to 8 carbon atoms, at least one hydrophilic (meth)acryloxy monomer, at least one hydrophilic N-vinylamide monomer, at least one methylene-containing pyrrolidone monomer, at least one vinyl ether monomer, or at least one allyl ether A monomer, at least one phosphorylcholine-containing vinyl monomer, N-2-hydroxyethyl vinyl carbamate, N-vinyloxycarbonyl-β-alanine, N-vinyloxycarbonyl-α-alanine, or (i) a combination thereof, wherein the at least one silicon-containing vinyl monomer comprises (i) at least one silicon-containing vinyl monomer containing a single ethylene-based unsaturated group selected from the group consisting of a tris(trialkylsiloxy)silyl group, and a (meth)acryloyloxy group, (meth)acryloylamino group, vinyl carbonate group, and vinyl carbamate group; (ii) at least one silicon-containing vinyl monomer containing a single ethylene-based unsaturated group selected from the group consisting of a bis(trialkylsilyloxy)-alkylsilyl group, and a (meth)acryloyloxy group, (meth)acryloylamino group, vinyl carbonate group, and vinyl carbamate group;(iii) at least one silicon-containing vinyl monomer comprising a) one single ethylene-based unsaturated group selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, and vinyl carbamate groups, and b) a polysiloxane chain having 2 to 30 siloxane units and terminated by an alkyl, hydroxyalkyl, or methoxyalkyl group; or (iv) a combination thereof. Claim 6 In paragraph 5, the second monomer mixture comprises at least one polysiloxane vinyl crosslinking agent of the following formula H, [Formula H] In the above formula: d1 is an integer from 30 to 500 and d2 is an integer from 1 to 75, provided that d2 / d1 is from 0.035 to 0.15 and X h1 is O or NR hN is R hN Silver, hydrogen, or C1-C 10 -alkyl and;R h0 It is hydrogen or methyl;R h1 and R h2 are independently substituted or non-substituted C1-C 10 alkylene divalent radical or -R h4 -OR h5 - is a divalent radical and R h4 and R h5 are independently substituted or non-substituted C1-C 10 It is an alkylene divalent radical and;R h3 is a monovalent radical of any one of the following chemical formulas Ha to He; [Chemical formula Ha] [Chemical Formula Hb] [Chemical formula Hc] [Chemical Formula Hd] [Chemical formula He] k1 is 0 or 1; m1 is an integer from 2 to 4; m2 is an integer from 1 to 5; m3 is an integer from 3 to 6; m4 is an integer from 2 to 5; R h6 It is hydrogen or methyl;R h7 is a C2-C6 hydrocarbon radical with an (m2+1) valence; R h8 is a C2-C6 hydrocarbon radical with an (m4+1) valence; R h9 is ethyl or hydroxymethyl;R h10 is methyl or hydroxymethyl;R h11 is hydroxyl or methoxy and; X h1 Silver -S- sulfur connector or -NR h12 - is the tertiary amino linker of and R h12 is a C1-C1 alkyl, hydroxyethyl, hydroxypropyl, or 2,3-dihydroxypropyl, and X h2 Is or It is a connector of and R h13 Silver, hydrogen, or C1-C 10 Alkyl, method. Claim 7 A method according to claim 5 or 6, wherein the second monomer mixture comprises (i) one single polydiorganosiloxane segment; and at least one polysiloxane vinyl crosslinker having two terminal ethylene-based unsaturated groups selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, and vinyl carbamate groups; and / or (ii) at least one chain-extended polysiloxane vinyl crosslinker having at least two polydiorganosiloxane segments and a covalent linker between each pair of polydiorganosiloxane segments and two terminal ethylene-based unsaturated groups, wherein the terminal ethylene-based unsaturated groups are selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, and vinyl carbamate groups. Claim 8 A method according to claim 5 or 6, wherein the sum of the amounts of components (a), (b), and (c) in the second monomer mixture is at least 60% by weight relative to the total weight of all polymerizable materials present in the second monomer mixture. Claim 9 In any one of claims 1 to 6, the at least one polymerizable material is (i) ethylene glycol di-(meth)acrylate, diethylene glycol di-(meth)acrylate, triethylene glycol di-(meth)acrylate, tetraethylene glycol di-(meth)acrylate, glycerol di(meth)acrylate, 1,3-propanediol di(meth)acrylate, 1,3-butanediol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, glycerol 1,3-diglycerolate di-(meth)acrylate, ethylenebis[oxy(2-hydroxypropane-1,3-diyl)]di-(meth)acrylate, bis[2-(meth)acryloxyethyl]phosphate, trimethylolpropane di(meth)acrylate, and 3,4-Bis[(meth)acryloyl]tetrahydrofuane, diacrylamide, dimethacrylamide, N,N-Di(meth)acryloyl-N-methylamine, N,N-Di(meth)acryloyl-N-ethylamine, N,N'-Methylene bis(meth)acrylamide, N,N'-Ethylene bis(meth)acrylamide, N,N'-Dihydroxyethylene bis(meth)acrylamide, N,N'-Propylene bis(meth)acrylamide, N,N'-2-Hydroxypropylene bis(meth)acrylamide, N,N'-2,3-Dihydroxybutylene bis(meth)acrylamide, 1,3-Bis(meth)acrylamide-propane-2-yl dihydrogen phosphate, piperazine diacrylamide, tetraethylene glycol divinyl ether, triethylene glycol (ii) at least one non-silicon vinyl crosslinking agent selected from the group consisting of divinyl ether, diethylene glycol divinyl ether, ethylene glycol divinyl ether, trialyl isocyanurate, trialyl cyanurate, trimethylpropane trimethacrylate, pentaerythritol tetramethacrylate, bisphenol A dimethacrylate, and combinations thereof; (ii) at least one C1-C8 alkyl (meth)acrylate, at least one C5-C 16 A method comprising: (iii) at least one non-silicon hydrophobic vinyl monomer comprising cycloalkyl (meth)acrylate, at least one aryl methacrylate, (meth)acrylonitrile, at least one fluorine-containing acrylic monomer, at least one vinyl alkanoate, at least one vinyloxyalkane, at least one substituted or unsubstituted styrene, vinyl toluene, vinyl chloride, vinylidene chloride, 1-butene, or a combination thereof; (iv) at least one UV-absorbing vinyl monomer; or (iv) a combination thereof. Claim 10 A method according to any one of claims 1 to 6, wherein the difference in concentration of each component of the at least one photoinitiator and the at least one polymerizable material between the first polymerizable fluid composition and the second polymerizable fluid composition is 4.0% or less. Claim 11 A method according to any one of claims 1 to 6, wherein the original layer of the second polymerizable fluid composition is irradiated for a time of 5% to 65% of the second curing time. Claim 12 A method according to any one of claims 1 to 6, wherein the at least one photochemical functional compound comprises at least one polymerizable UV / HEVL absorbing compound. Claim 13 A method according to any one of claims 1 to 6, wherein the at least one photochemical functional compound comprises at least one polymerizable fluorescent compound. Claim 14 In any one of claims 1 to 6, the second polymerizable fluid composition comprises naphtopyran, indeno-fused naphtopyran, heterocyclic ring-fused naphtopyran, benzopyran, phenantropyran, quinopyran, quinolinopyran, fluoroantenopyran, anthracene-fused pyran, tetracene-fused pyran, spiro(benzindolin)naphtopyran, spiro(indolin)naphtopyran, spiro(indolin)benzopyran, spiro(indolin)quinopyran, spiro(indolin)pyran, naphthoxazane, spirobenzopyran, spirobenzothiopyran, naphthacenedione, benzoxazane, spirooxazane, naphthoxazane, spiro(benzindolin)naphthoxazane, spiro(indolin)naphthoxazane, spiro(indolin)pyrido-benzoxazane, Spiro(indoline)-benzoate, Spiro(benzindolin)-benzoate, Spiro(benzindolin)pyridobenzoate, Spiro(indoline)fluolanthenoxoate, Spiro(indoline)quinoxoate, Spiropiperidine-naphtopyran, Pyro(indoline)pyronobenzoate, Benzospiropyran, Naphtospiropyran, Spirobenzoate-pyrrolopyridine, Spironaphtok-pyrrolopyridine, Spiro-oxazepine-benzoate, Spiro(indoline)benzophyroloxoate, Spiro(indoline)quinazolino-oxoate, Spiro(indoline)anthracenobenzoate, Benzofurobenzopyran, Benzothienobenzopyran, A method comprising at least one photochromic compound comprising naphthofurobenzopyran, benzopyrano-fused naphthofyran, spiro(isoindoline)-naphthoxazine, spiro(isoindoline)benzoxazine, or a mixture thereof. Claim 15 A method according to claim 14, wherein at least one photochromic compound is polymerizable and comprises an ethylene-based unsaturated group. Claim 16 In paragraph 15, the at least one photochromic compound is a coupling reaction product of a reactive (meth)acrylamido or (meth)acryloxy monomer having a first reactive functional group and a reactive photochromic compound having a second reactive functional group in the absence or presence of a coupling agent in a coupling reaction, wherein the first reactive functional group is -COCl, -COBr, -COOH, -NHR N2 , -NCO, -OH, -CHO, , , or Selected from the group consisting of, and the second reactive functional group is -COOH, -NHR N2 , , , , -NCO, -OH, -SH, -CHO, , , or Selected from the group consisting of, where R0 is hydrogen or methyl and R N2 is hydrogen, linear or branched C1-C 15 A method in which alkyl, cyclohexyl, cyclopentyl, substituted or unsubstituted phenyl, or substituted or unsubstituted phenyl-C1-C6 alkyl. Claim 17 In paragraph 16, the reactive (meth)acrylamido or (meth)acryloxy monomer is a (meth)acryloyl halide of CH2=CH─COX or CH2=CCH3─COX where X = Cl or Br, N-hydroxysuccinimide ester of (meth)acrylic acid, glycidyl (meth)acrylate, isocyanato-C2-C6 alkyl (meth)acrylate, amino-C2-C6 alkyl (meth)acrylamide, C1-C6 alkylamino-C2-C6 alkyl (meth)acrylamide, (meth)acrylic acid, C2-C4 alkylacrylic acid, N-2-acrylamidoglycolic acid, 3-(acryloyloxy)propanoic acid, C2-C6 hydroxylalkyl (meth)acrylate, C2-C6 hydroxyalkyl (meth)acrylamide, azlactone-containing vinyl Monomer, aziridinyl C1-C 12 A method selected from the group consisting of alkyl (meth)acrylates, acrolein, metacrolein, crotonaldehyde, and combinations thereof. Claim 18 In paragraph 16, the reactive photochromic compound is 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-propyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxy-13-propyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-(2-hydroxycarbonylethyl)carboxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxymethyl-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-(2-hydroxycarbonylethyl)carboxymethyl-13-methyl-3H,13H-indeno[2',3':3,4]-naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran;3,3-Bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno-[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-11-phenyl-13-hydroxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-methoxyphenyl)-11-phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,7,10,11-tetramethyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno[2',3':3,4]-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11-(4-(4,5-diphenyl-1H-imidazole-2-yl)phenyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6-methoxy-7-(3-hydroxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3,3-di(4-methoxyphenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)-carboxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-hydroxyethoxy)-ethoxy)-indeno[2,1-f]naphtho[1,2-b]pyran;3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-diphenyl-13-hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11-dimethyl-13-butyl-13-hydroxy-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13,13-diethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13,13-dipropyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-Bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13-carbomethoxy-13-methyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-diphenyl-6,7-dimethoxy-13-methyl-13-methyl-13-hydroxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-diphenyl-6,7,10,11-tetramethoxy-13-ethyl-13-methyl-13-hydroxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 6,7-Dimethoxy-2,2-Diphenyl-13-hydroxy-13-butyl-2H,13H-Indeno[1',2':4,3]Naphtho[1,2-b]pyran; 6,7-Dimethoxy-2,2-Diphenyl-13-hydroxy-13-methyl-2H,13H-Indeno[1',2':4,3]Naphtho[1,2-b]pyran; 6,7-Dimethoxy-2,2-Diphenyl-13-hydroxy-2H,13H-Indeno[1',2':4,3]Naphtho[1,2-b]pyran; 3-(4-allyloxyphenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran;3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(piperazine-1-yl)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(4-hydroxybenzamido)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-vinyl-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(carboxylic acid)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2',3':3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3-(4-fluorophenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-hydroxyethoxyphenyl)-3-(4-methoxyphenyl)-11-(4-(N,N-dimethylamino)phenyl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(2,4-dimethoxyphenyl)-phenyl-6,11-dimethoxy-13-methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran;3-(4-methoxyphenyl)-3-(3-methyl-4-methoxyphenyl)-13-hydroxy-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-deno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7-dimethoxy-13-hydroxy-13-methyl-3H,13H-deno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-13-oxo-3H,13H-deno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6-methoxy-7-morpholino-13-methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6,11-dimethoxy-13-methyl-13-methyl-13-hydroxyethoxy-ethoxy-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-oxo-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran;3-phenyl-3-(4-hydroxyethoxyphenyl)-6-methoxy-7-morpholino-13,13-dimethyl-3H,13H-indeno-[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxyethoxy-phenyl)-6-methoxy-7-morpholino-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxyethoxy)phenyl)-6-methoxy-7-piperidino-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-(2-hydroxycarbonylethyl)-carboxyethoxy)phenyl)-6-methoxy-7-piperidino-13,13-dimethyl-3H,13H-indene[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-hydroxyphenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-hydroxyethoxy)phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxyethoxy)phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxy-phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-(2-hydroxyethyl)piperazine-1-yl)phenyl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-(2-(2-hydroxycarbonylethyl)-carboxyethyl)piperazine-1-yl)phenyl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-piperazinyl-13,13-dimethyl-3H,13H-indene[2',3':3,4]naphtho[1,2-b]pyran;3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(3-hydroxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)carboxymethylenepiperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4-hydroxypifenidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)-carboxypifenidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-methoxyphenyl-piperazine-1-yl)phenyl)-13,13-dimethyl-6-methoxy-7-hydroxy-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-methoxyphenyl-piperazine-1-yl)phenyl)-13,13-dimethyl-6-methoxy-7-(2-hydroxy-2-methyl-3-butin-4-yl)-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-hydroxymethylene-piperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonyl-ethyl)carboxymethylene-piperidine-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3.4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)carboxymethylene-piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran;3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)-carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-piperazinyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6,11-dimethyl-13-hydroxy-13-(1-oxo-methoxyprop-2-yl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)-phenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)phenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6,11-dimethoxy-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6-methoxy-7-piperidinyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(3-methylpiperazine-1-yl)phenyl)-6-methoxy-7-(decahydroisoquinoline-2-yl)-11-tert-butyl-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-16-(ethoxycanobyl)methyl-16-hydroxy-3,16-dihydrobenzofuro-[2',3':7,8]indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-16-(ethoxycanobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro [2”,3”:6',7']indeno-[3',2':4,3]naphtho[1,2-b]pyran;3-phenyl-3-(4-morpholinophenyl)-16-(ethoxycanobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro[2”,3”:6',7']deno[3',2':4,3]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-(ethoxycarbonyl)methyl-16-hydroxy-3,16-dihydro-benzofuro[2',3':7,8]deno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16-ethyl-16H-benzofuro[2',3':7,8] indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16H-benzofuro[2”,3”:6,7]indeno[3',2':4,3]naphtho-[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16-ethyl-16H-benzofuro[2”,3”:6,7]-indeno[3',2':4,3]naphtho[1,2-b]pyran; A method comprising 3-(4-methoxyphenyl)-3-(2,3-dihydrobenzofuro-5-yl)-13-hydroxy-13-methyl-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(2,3-dihydrobenzofuro-5-yl)-6,11-difluoro-13-hydroxy-13-(1-oxo-methoxyprop-2-yl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran, or a mixture thereof.; Claim 19 In paragraph 16, the reactive photochromic compound is 2,2-di(4-fluorophenyl)-5-hydroxycarbonyl-6-phenyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methylphenyl)-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-hydroxy-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-vinyl-2H-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-hydroxycarbonyl-2H-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(2-hydroxyethoxy)ethoxy-[2H]-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxycarbonyl-6-phenyl-9-(2-hydroxyethoxy)-[2H]-naphtho[1,2-b]pyran; 2,2-Bis(4-methoxyphenyl)-5-methoxy-carbonyl-6-(4-(2-hydroxyethoxy)phenyl)-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-hydroxyethoxylcarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-hydroxyethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-(2-hydroxyethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-phenyl-2H-naphtho[1,2-b]pyran;2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(3-aminophenyl)-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-2,5,7-trihydro-7-methylidine-5-oxo-furo-[3',4':3,4]naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-13-hydroxy-13-methyl-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-9-methoxycarbonyl-8-(2-hydroxyethoxy)ethoxy-[3H]-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-8,9-dimethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carbomethoxy-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-methylol-6-(3-dimethylaminopropyl)-methylamino-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-2,5,7-trihydro-7-methylidene-5-oxofuro-[3',4':3,4]naphtho[1,2-b]pyran; 2,2-spiroadamantylene-5-phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl)-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-spiro-admamtylene-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran, 3,3-diphenyl-8-hydroxy-9-carbopropoxy-3H-naphtho[2,1-b]pyran; 2,2,5-triphenyl-6-carboethoxy-2H-naphtho[1,2-b]pyran;2,2,6-triphenyl-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)-ethoxy)ethoxy)carbonyl-[2H]-naphtho[1,2-b]pyran; 2,2,6-triphenyl-5-(2-(2-(2-oxiran-2-ylmethoxy)ethoxy)ethoxy)-ethoxycarbonyl)-[2H]-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-tert-butyl-5-methoxy-carbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)-ethoxyphenyl)-2-phenyl-5-methoxycarbonyl-6-methyl-9-methoxy-[2H]-naphtho[1,2-b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-2-phenyl-5-methoxycarbonyl-6-(2-(2-methylprop-2-enoxyloxy)ethoxy)-[2H]-naphtho[1,2-b]pyran; 3-(4-(2-(2-hydroxyethoxy)-ethoxy)ethoxyphenyl)-3-phenyl-9-methoxycarbonyl-8-methoxy-[3H]-naphtho[1,2-b]pyran; 2-(4-morpholinophenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(9-ethylcarbazole-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(9-phenylcarbazole-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-dimethylaminophenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 3-(2-fluorophenyl)-3-(4-methoxyphenyl-8-hydroxy-9-carbopropoxy-3H-naphtho[2,1-b]pyran; 3-(2-fluorophenyl)-3-(4-methoxyphenyl-8-hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran; 3-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl-8-hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran;3-(2,4,6-trifluorophenyl)-3-(2,4,6-trimethoxy-1-naphthyl)-8-acetyl-9-carbonylloyl-3H-naphtho[2,1-b]pyran; 3-(4-methoxyphenyl)-3-(2-methyl-2,3-dihydrobenzofuro-5-yl)-6-methoxy-12-hydroxymethyl-11-phenyl-3H-phenantro[1,2-b]pyran; 5,5-bis(4-methoxyphenyl)-8-methylol-5H-fluoranteno[3,2-b]pyran; or a mixture thereof, a method.; Claim 20 In paragraph 16, the reactive photochromic compound is 1-hydroxyethyl-3,3-dimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-hydroxypropyl-3,3-dimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-aminoethyl-3,3-dimethyl-5-chlorospiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-hydroxyethyl-3,3-dimethyl-8'-methoxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-(p-vinylphenyl)-3,3-dimethyl-5,6-dichlorospiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9'-hydroxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5'-hydroxymethylspiro-[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9'-aminospiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5-chloro-8'-hydroxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-9'-vinylbenzoyoxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-5'-hydroxymethylpiperidinospironaphthooxazine; 1,3,3-trimethyl-9'-hydroxyspiro[indolin-2,3'-[3H]-pyrido-[2,1-b][1,4]benzoxazine]; 5-hydroxy-6'-cyano-1,3,3-trimethyl-spiro-[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-hydroxy-6'-phenylsulfonyl-1,3,3-trimethyl-spiro-[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5'formyl-1,3,3-trimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-dihydro-6'-piperazino-1,3,3-trimethylspiro[2H indole-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine;1,3-Dihydro-6'-(4-hydroxyethyl)piperazino-1,3,3-trimethylspiro[2H indole-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-Dihydro-9'-hydroxy-1,3,3-trimethylspiro[2H indole-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3,3,4,5-pentamethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]naphtho[2,1-b][1,4]oxazine; 1,3,3,5,6-pentamethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]napt[2,1-b][1,4]oxazine; 1-propyl-3,3,4,5-tetramethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]napt[2,1-b][1,4]oxazine; 1-propyl-3,3,5,6-tetramethyl-9'-methoxycarbonyl-8'-hydroxy-spiro[indolin-2,3'-[3H]napt[2,1-b][1,4]oxazine; 1-Methoxyethyl-3,3-Dimethyl-9'-Allyloxycarbonyl-8'-Chloroactoxy-spiro[Indolin-2,3'-[3H]Napt[2,1-b][1,4]Oxazine; 1-Allyl-3,3-Spirocyclohexyl-9'-Benzyloxycarbonyl-8'-Chloroactoxy-spiro[Indolin-2,3'-[3H]Napt-[2,1-b][1,4]Oxazine; 5-Amino-1,3,3-Trimethyl-spiro[Indolin-2,3'-[3H]-Pyrido[3,4-f][1,4]-Benzoxazine; 6-Hydroxy-1',3',3',4',5'-Pentamethylspiro[2H-1,4-Benzoxazine-2,2'-Indolin]; 6-hydroxy-1',3',3',5',6'-pentamethylspiro[2H-1,4-benzoxazine-2,2'-indolin]; 5,7-dimethoxy-1'-hydroxy-carbonylethyl-3',3'-dimethylspiro[2H-1,4-benzoxazine-2,2'-indolin]; 7-methoxy-1'-hydroxy-ethyl-3',3'-dimethylspiro[2H-1,4-benzoxazine-2,2'-indolin]; 9'-hydroxy-1-methylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 5-chloro-9'-hydroxy-1-methylspiro-[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine];8'-hydroxy-1-methylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 8'-hydroxy-5-methoxy-1-methylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 8'-hydroxy-1,4,5-trimethylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9'-hydroxy-1-isopropylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9'-hydroxy-1-hexadecyl-spiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9'-hydroxy-1-octadecylspiro[indolin-2,3'-(3H)-naphtho(2,1-b)-1,4-oxazine]; 1,1”-(1,5-pentanediyl)bis[3,3-dimethyl]-9'-hydroxy-spiro[indolin-2,3'-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-[1,4-phenylenebis(methylene)]bis[3,3-dimethyl]-5'-hydroxymethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-(1,4-butanediyl)bis[5,6-dichloro-3,3-dimethyl]-8'-hydroxyspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9'-hydroxypiperidinospyronafthoxazine; 3-carboxyethyl-1,1-dimethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1-carboxyethyl-3,3-dimethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 1,1-dimethyl-3-hydroxyethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 3,3-dimethyl-1-hydroxyethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 3-carboxyethyl-1,1-dimethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine];1-Carboxyethyl-3,3-dimethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine]; 1,1-dimethyl-3-hydroxyethyl-9'-methoxyspiro[benz[e]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine]; 3,3-dimethyl-1-hydroxyethyl-9'-methoxyspiro[benz[g]-indolin-2,3'-[3H]-pyrido[2,1-b][1,4]benzoxazine]; A method comprising: 5-amino-5'-(2-benzthiazolyl)-1,3,3-trimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-amino-5'-(5'-(2-hydroxyphenyl)-2-oxadiazolyl)-1-isopropyl-3,3-dimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-amino-5'-(5'-phenyl-2-oxadiazolyl)-1,3,3-trimethylspiro[indolin-2,3'-[3H]-naphtho[2,1-b][1,4]oxazine]; or a mixture thereof.; Claim 21 In claim 16, the reactive photochromic compound is 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2-hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; or a mixture thereof. Claim 22 A hydrogel contact lens obtained according to the method of any one of claims 1 to 6.
Citation Information
Patent Citations
Facilitating release of silicone hydrogel ophthalmic lenses
KR1020070080847A
Methods and systems for releasing silicone hydrogel ophthalmic lenses using surfactants
KR1020080098365A
Process for making ophthalmic lenses
KR1020080113253A
Methods and systems for processing silicone hydrogel ophthalmic lenses for improved lens transfer
KR1020100136468A
Method for making silicone hydrogel contact lenses
KR1020110105813A
